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V. General introduction 
 
Targeted inhibition of mTOR/PI3K/Akt in clinical cancer therapies 
Cancer deaths in U.S. have fallen dramatically since the early 90’s but the  new cancer cases is expected 
to jump from 1.7 million in 2017 to 2.3 million in 2030 (“AACR Cancer Progress Report 2017”,  2017).  
The mTOR/PI3K/Akt pathway is the most frequently altered network in human neoplasms. Mutations 
leading to the activation of this pathway is associated with cancer initiation, progression, metastasis and 
drug resistance. Since many years, multiple molecular targets were identified for therapy and the 
signaling pathway has been thoroughly reviewed (Engelman 2009; Laplante et al. 2012; Yuan & Cantley 
2008; Courtney et al. 2010; Guri & Hall 2016; Thorpe et al. 2015). There are plenty of redundancy and 
feedback between the RAS–RAF–MEK–ERK and PI3K–AKT–mTOR signaling networks (Fruman & 
Rommel 2014). Almost all key components along these two signaling axes, such as BRAF, MEK, PI3K, 
Akt, and mTOR, have been therapeutically targeted to allow for serial and parallel blockade of these 
two pathways (Wicki et al. 2016).  
 
mTORC1/2. mTOR is a serine-threonine kinase in the PI3K-related kinase (PIKK) family, involved in 
several central role for the cell such as mRNA translation, metabolism or autophagy (Hall 2016). It is 
part of two distinct protein complexes know as mTOR Complex 1 (mTORC1) and mTOR Complex 2 
(mTORC2). mTORC1 is defined by his three major components, mTOR, Raptor and mLST8. In 
addition, two other component are part of the mTORC1, PRAS40 and DEPTOR (Peterson et al. 2009) 
and the rapamycin-FKBP12 complex binds to the FRB domain of mTOR and inhibits it (Yang et al., 
2013). mTORC1 functions as a downstream effector for many frequently mutated oncogenic pathways, 
including the PI3K/Akt pathway as well as the Ras/Raf/Mek/Erk (MAPK) pathway, resulting in 
mTORC1 hyperactivation in a high percentage of human cancers (Saxton & Sabatini 2017). mTORC2 
is characterized by its insensitivity to acute rapamycin treatment and like mTORC1, mTORC2 contains 
mTOR and mLST8 which are rapamycin derivatives (Saxton & Sabatini 2017). mTORC2 also contains 
DEPTOR, Rictor, mSin1 and Protor1/2 (Jacinto et al. 2006; Pearce et al. 2007).   
 
Historically two classes of mTOR inhibitor were developed: One class is rapalogues, like everolimus 
and temsirolimus, that inhibit allosterically mTOR in mTORC1. Most patients tend to develop resistance 
from allosteric inhibitors and combinations with other compounds has revealed to be challenging 
regarding the toxicity. The second class is ATP competitive inhibitors inhibit mTOR in both mTORC1 
and mTORC2. By inhibiting both mTOR complexes, the ATP-competitive inhibitors are theoretically 





rapalogues have yet been reported (Turner et al. 2017a). No drug from the second category is yet 
approved for treatment. This subject is further developed in the introduction of the chapter VIII. 
 
 PI3K. Phosphorylation of membrane phospholipids is key to signal transduction and has a major role 
in driving cancer initiation and progression (Whitman et al. 1988). PI3K are heterodimers comprising a 
110 kDa catalytic isoform encoded by one of the four genes (PIK3CA, PIK3CB, PIK3CD and PIK3CG) 
and a 85kDa regulatory subunit encoded by three genes (PIK3R1, PIK3R2 and PIK3R3). The catalytic 
isoforms share considerable sequence homology, produce the same lipid product (PtdIns(3,4,5)P3) and 
can be activated by GTPases and RTK (Fritsch et al. 2013). PI3K activation initiates a signal 
transduction cascade that promotes cancer cell growth, survival and metabolism. The PI3K/Akt pathway 
is mainly negatively regulated by PTEN, a major tumor suppressor (Maehama & Dixon 1998). In human 
cancer, only PIK3CA (encoding p110α) is frequently mutated (Zardavas et al. 2014; Samuels et al. 
2004). 
 
Three strategies are currently used to inhibit PI3K: pan-isoform PI3K, isoform-specific PI3K and dual 
PI3K/mTOR inhibition. Pan-isoform PI3K inhibitor such as buparlisib and pictilisib inhibit all four 
isoforms and have therefore been associated with many side effects. Alpha-selective inhibitors like 
tselisib and alpelisib inhibit the driver oncogene and thus should reduce toxicities. Most of the dual non-
selective inhibitors trials ceased due to poor PK properties or extended toxicities. This subject is further 







A special case: the AGC kinases 
AGC kinases are part of the mTOR/PI3K/Akt pathway or closely related in many ways. The rest of this 
general introduction and part of the general discussion has been published under the title “Inhibition of 
Akt and other AGC kinases: A target for clinical cancer therapy?” in Seminar Cancer Biology in 









The rationale for AGC kinase-directed therapy in clinical cancer care 
AGC kinases are a subgroup of Ser/Thr protein kinases. Based on the structure of their catalytic kinase 
domain, kinases are related to cAMP-dependent protein kinase 1 (PKA), cGMP-dependent protein 
kinase (PKG) and protein kinase C (PKC), building the acronym AGC (Hanks & Hunter 1995). The 
AGC family contains 60 of the 518 human protein kinases and 42 possess functional domains other than 
the kinase core, which are mostly involved in regulating kinase activity and localization (Manning et al. 
2002). 
 
Recent studies have identified around 1100 cancer drivers, both oncogenes and tumor suppressor genes. 
Roughly 10% of those cancer drivers correspond to protein kinases, making this group of enzymes a 
prime target for cancer therapy. Although some of these kinases are mutated at high frequency (>10% 
in a given cancer entity), the mutation rate of most cancer drivers is low. The most common genetic 
aberration of protein kinases are somatic mutations, followed by copy number aberrations and gene 
fusions. Of the eight main classes of kinases, by far the most frequent genomic aberrations have been 
identified in tyrosine kinases (TK), followed by tyrosine-like kinases (TLK) and homologues of yeast 
sterile 7 (STE).  
 
Cancer driving genomic alterations of AGC kinases are less frequent. However, a number of AGC 
kinases have been identified to contribute to cancer development and progression, including Akt 1, Akt 
3, PRKCI, PRKCZ, RPS6KB1, and SGK1 (Fleuren et al. 2016). The role of those kinases in 
tumorigenesis and cancer progression depends on the context in which a mutation occurs. In cervical 
cancer for example, tumor cells only become dependent from SGK2 upon loss of p53 (Baldwin et al. 
2010). This has implications for the development of clinical biomarkers.  
 
Predictive biomarkers in oncology 
True predictive markers are able to estimate the likelihood of clinical benefit of a specific therapy in an 
individual. Predictive markers can be genetic by nature but markers based on RNA arrays or protein 
expression have been validated in the clinic as well. Examples for predictive markers in oncology 
include Her2 amplification as well as the expression of the oestrogen and progesterone receptor in breast 
cancer, the Braf V600 mutation in melanoma, EGFR mutation and Alk translocation in non-small cell 
lung cancer (NSCLC), and Ras mutation in colorectal cancer. For genomic markers, it is not enough to 
understand the (activating, inactivating or neutral) effect of a sequence variation in order to predict 
clinical response to a targeted agent. First, the predictive value of a biomarker must be assessed in a way 
that takes into account the biological context, e.g., the tissue of origin, the co-occurrence of other 





predictive value. In the BELLE-2 trial (Forte et al. 2016), activating PI3K mutations found in cell-free 
tumor DNA predicted response to PI3K-mTOR inhibition, while PI3K mutations in solid tumor biopsies 
did not. Finally, the predictive value of a genomic alteration also depends on the threshold of detection. 
The best-known example for this is Ras. Ras mutations predict resistance against anti-EGFR antibodies. 
Sequencing Ras with a method sensitive enough to detect Ras mutations in 10-15% or more of the tumor 
cells (i.e., by Sanger sequencing) results in an inferior predictive value of Ras compared to sequencing 
with a method that allows for a detection of the mutation in as few as 1-5% of the tumor cells (e.g., by 
ion torrent based next-generation sequencing). However, if Ras is found mutated by very sensitive 
sequencing techniques (e.g., droplet digital PCR) in less than 0.1-1% of the tumor cells, the predictive 
value of the marker starts to drop again (Tougeron et al. 2013; Laurent-Puig et al. 2015).  
 
In summary, the predictive value of a (genetic) marker depends on the biological context, the source of 
the biomarker (e.g., liquid versus solid tissue biopsy) and the sensitivity of the detection method. 
Biomarkers of response must be integrated into the development of a pharmaceutical compound, and 
they need to be tested in a prospective, randomized, and double-blinded trial. For most cancer therapies, 
predictive markers are not available. No robust biomarker for prediction of response to AGC kinase 
inhibitors has been identified so far.  
 
Approved AGC kinase inhibitors in clinical use 
Apart from the gold-compound aurothiomalate, the only approved structural AGC kinase inhibitor is 
miltefosine (hexadecylphosphocholine). Miltefosine is an oral synthetic alkylphosphocholine (ALP), 
structurally similar to endogenous phospholipids. It can be incorporated into cell membranes and inhibits 
the membrane-linked protein kinase C (PKC) as well as Akt signalling (Uberall et al. 1991; Ruiter et al. 
2003). Miltefosine was evaluated in patients with soft tissue sarcomas (Verweij, Krzemieniecki, et al. 
1993), colorectal cancer (Planting et al. 1993) and squamous cell carcinoma of the head and neck 
(Verweij, Gandia, et al. 1993). Unfortunately, the dose required for an anti-tumor effect was above the 
maximum tolerated dose (MTD) and thus this drug was not developed as a systemic anti-cancer drug. 
Some preclinical studies tried to reduce the toxicity by encapsulating miltefosine in pegylated liposomes. 
This was not successful (Papagiannaros et al. 2006; Teymouri et al. 2015; Laplante et al. 2012). Applied 
locally, it has a limited effect against cutaneous breast cancer (Clive et al. 1999; Leonard et al. 2001) 
and cutaneous lymphoma (Sindermann et al. 1993). At a low systemic dose, miltefosine (Impavido®) 
is approved by the FDA against visceral, mucosal and cutaneous leishmaniasis.  
 
Its derivative perifosine is better tolerated (Hilgard et al. 1997), inhibits AKT, and activates JNK 
(Hideshima 2006; Fu et al. 2010; Chiarini et al. 2008). Alkylphosphocholines may increase the effect of 





showed a radiosensitizing effect in prostate cancer (Gao et al. 2011), gliomablastoma (Rübel et al. 2006), 
lymphoma (Ruiter et al. 1999) and squamous cell carcinoma (Vink et al. 2006). It was tested as single 
agent in solid tumors but with limited antitumor activity: in a phase 3 trial in patients with advanced 
colorectal cancer it was found to be ineffective in an otherwise unselected population (Bendell 2012). 
A phase 3 trial of perifosine in combination with bortezomib (a proteasome inhibitor) and 
dexamethasone was stopped based on a futility analysis. Perifosine is the most extensively studied ALP 
in combination with other anti-cancer treatments, such as radiation, mTOR inhibition, and conventional 
chemotherapy (van Blitterswijk & Verheij 2013). For example, based on a synergistic cytotoxic activity 
against lymphoma cell lines in vitro and in vivo (Locatelli et al. 2013), perifosine was tested in a phase 
2 trial in combination with sorafenib in patients with Hodgkin’s lymphoma (Guidetti et al. 2014).  So 
far, there are no positive clinical data for perifosine-based combination therapies. 
 
Development of AGC kinase inhibitors for cancer therapy 
A range of AGC kinase inhibitors have entered clinical development. Table V-1 offers an overview on 
the most recent trials with a series of AGC kinase-directed inhibitors while Figure V-1 gives a simplified 
graphical overview of the pathways affected by these inhibitors. 
 
 
Figure V-1 A simplified overview of the AKT, p70S6K and PKC signaling networks. 
Clinical trials with AGC inhibitors are mostly running in this pathway. Red bars represent inhibition, 
bluearrows represent activation and red boxes indicate the inhibitors and their targets. Part of the 
crosstalk between the different pathways has been omitted for simplification. 
 
Akt. Most Akt inhibitors in clinical development are pan-Akt inhibitors. MK-2206 is an allosteric oral 
Akt1 & 2 inhibitor with an additional but low potency against Akt3 (Yan 2014; Hirai et al. 2010). 





unlike ATP-competitive inhibitors (Okuzumi et al. 2009). Studies combining MK-2206 with cisplatin 
showed additive or synergistic activity in vitro and in vivo in gastric (Li et al. 2013) and lung cancer 
(Galvez-Peralta et al. 2014). Sensitivity to carboplatin and paclitaxel was also increased in breast cancer 
(Sangai et al. 2012), gastric cancer (Almhanna et al. 2013), and melanoma cell lines (Rebecca et al. 
2014). The half-life of MK-2206 is more than 40 hours, arguing in favour of an alternate-day dosing 
schedule (Yap et al. 2014). The first-in-man dose escalation trial investigated tolerability, safety, and 
maximal tolerated dose (MTD) of the compound in 33 patients with advanced solid tumors (Yap et al. 
2011). Paired biopsies were mandatory. Phosphorylated serine 473 declined in all assessed tumor 
biopsies, indicating that the target was hit. Drug-related adverse events included skin rash (52%), nausea 
(36%), pruritus (24%), hyperglycemia (21%), and diarrhea (21%). Skin rash, pruritus and 
hyperglycemia are typical side-effects occurring upon inhibition of the PI3K-mTOR axis. The rate of 
hyperglycemia was lower than in trials investigating pan-PI3K or PI3K-alpha inhibitors (with 
hyperglycemia rates above 50%), but higher than observed in patients on oral mTOR inhibitors (the rate 
of hyperglycemia of Everolimus for example is roughly 10%). Thus, the side-effect profile is within the 
expected range for this class of compounds, and adverse events are at least in part related to the 
downstream blockade of insulin signalling. The MTD was 60mg on alternate days. Three minor 
responses were observed. One of the responding patients suffered from a PTEN-deficient and Kras 
G12D mutant pancreatic adenocarcinoma. The two others had metastatic neuroendocrine cancers of the 
pancreas. This is in line with the fact that mTOR inhibitors such as everolimus are clinically effective 








Table V-1 : Recent clinical trials with AGC kinase inhibitors. The most advanced clinical studies were 
selected. 
 
A second phase 1 trial with the same compound in 50 children with refractory or recurrent malignancies 
failed to show objective responses (Fouladi et al. 2014). Prolonged stable disease (3 or more months) 
was observed in 7 patients. The safety profile was comparable to the first-in-man trial.  
A phase 2 trial investigated the combination of MK-2206 together with selumetinib, a MEK 1/2 inhibitor 
(Do et al. 2015). 21 patients with advanced colorectal cancer were enrolled. Akt and Erk phosphorylation 
were assessed in sequential biopsies. Significant dual target inhibition, defined by downregulation of 
pAkt and pErk by ≥70%, was not achieved. Since there was no correlation between the PK level and the 
degree of pAkt/pErk downregulation, it is difficult to decide whether this was due to a suboptimal dose 
and schedule or rather to an AKT/MEK independent activation of Erk. Gastrointestinal, hepatic, 
dermatologic and hematologic adverse events were observed, including 3 patients with subretinal fluid 
accumulation as assessed by ocular coherence tomography (OCT). Overall the toxicity profile was again 
in line with previous data from AKT and MEK inhibitors, including the mentioned reversible subretinal 
oedema caused by MEK inhibition.  
 
GDC-0068 (Ipatasertib) is a competitive pan-Akt inhibitor (Lin Kui 2011). It showed efficacy in vitro 
and in a broad spectrum of human cancer xenograft models. Consistent with findings in other Akt 
Target Subunit Compound Name Company Mechanism Phase Indication Combination Comparator NCT Start Status
AKT pan-AKT
MK-2206 - Merck allosteric Phase 2
Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal 
Cancer
- - NCT01283035 2011 Completed
Phase 2 Metastatic Neuroendocrine Tumors - - NCT01169649 2010 Completed
Phase 2 Relapsed Acute Myelogenous Leukemia - - NCT01253447 2010 Completed
Phase 2 Relapsed Lymphoma - - NCT01258998 2010 Completed
Phase 2 Relapsed Diffuse Large-B Cell Lymphoma - - NCT01481129 2011 Completed
Phase 2  Advanced Gastric and Gastroesophageal Junction Cancer - - NCT01260701 2011 Completed
Phase 2 Refractory Biliary Cancers - - NCT01425879 2011 Completed
Phase 2
Non-small Cell Lung Cancer Progredient After Erlotinib 
Therapy
Erlotinib - NCT01294306 2011 Completed
Phase 2 Metastatic Pancreatic Cancer After Prior Chemotherapy AZD6244 mFOLFOX NCT01658943 2012 Completed
Phase 2 Recurrent and Metastatic Nasopharyngeal Carcinoma - - NCT01370070 2011 Ongoing
Phase 2
Progressive, Recurrent/Metastatic Adenoid Cystic 
Carcinoma
- - NCT01604772 2012 Ongoing
Phase 2 Recurrent or Advanced Endometrial Cancer -  PIK3CA Mutation Stratified NCT01307631 2011 Ongoing
Phase 2
Previously Treated Metastatic Colorectal Cancer Patients 
Enriched for PTEN Loss and PIK3CA Mutation
- - NCT01802320 2013 Ongoing
Phase 2
Patients With Advanced Breast Cancer Who Have Tumors 
With a PIK3CA Mutation, or an AKT Mutation, and/or PTEN 
Loss/PTEN Mutation
- - NCT01277757 2011 Ongoing
Phase 2 Refractory Renal Cell Carcinoma - Everolimus NCT01239342 2011 Ongoing
Phase 2
Clinical Stage 2 or 3 PIK3CA Mutant Estrogen Receptor 
Positive and HER2 Negative Invasive Breast Cancer
Anastrozole if 
Postmenopausal, Anastrozole 
and Goserelin if 
Premenopausal
- NCT01776008 2013 Ongoing
Phase 2
Prostate with Rising PSA at High-Risk of Progression After 
Primary Therapy
Bicalutamide - NCT01251861 2010 Ongoing
GDC-0068 Ipatasertib Genentec allosteric Phase 2








- NCT02162719 2014 Ongoing
Phase 2b Glioblastoma / Gliosarcoma - MK-3475 (Pembrolizumab) NCT02430363 2015 Recruiting
Phase 2 Early Stage Triple Negative Breast Cancer Paclitaxel - NCT02301988 2015 Recruiting
GSK2110183 Afuretesib GSK ATP-competitive Phase 2
Relapsed and Refractory Chronic Lymphocytic Leukemia 
(CLL)
GSK2110183 (Afuresertib) - NCT01532700 2012 Ongoing
GSK2141795 Uprosertib GSK ATP-competitive Phase 2 BRAF Wild-type Melanoma GSK1120212 (Trametinib) - NCT01941927 2013 Ongoing
AZD5363 - AstraZeneca n.k. Phase 2 Metastatic Breast Cancer -
AZD2014, AZD4547, AZD8931, Selumetinib, 
Vandetanib, Bicalutamide, Olaparib, 
Anthracyclines, Taxanes, cyclophosphamide, 
DNA intercalators, Methotrexate, vinca 
alkaloids, Platinum based chemotherapies, 
Bevacizumab, Mitomycine C, Eribuline, 
MEDI4736.
NCT02299999 2014 Recruiting
Phase 2 Metastatic Non-small Cell Lung Cancer -
AZD2014, AZD4547, AZD8931, Selumetinib, 
Vandetanib, Erlotinib, Pemetrexed, MEDI4736
NCT02117167 2014 Recruiting
Phase 2 Triple-Negative Advanced or Metastatic Breast Cancer Paclitaxel - NCT02423603 2014 Recruiting
Phase 2 Metastatic Castration‐Resistant Prostate Cancer Enzalutamide (MDV3100) - NCT02525068 2015 Recruiting
Phase 2
Advanced Gastric Adenocarcinoma Patients Harboring 
PIK3CA Mutation and/or PIK3CA Amplification
Paclitaxel - NCT02451956 2015 Recruiting
Phase 2
Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric 
Adenocarcinoma
Paclitaxel AZD2014 Plus Paclitaxel NCT02449655 2015 Recruiting
Phase 2 NSCLC -
AZD4547, AZD2014, Palbociclib, Crizotinib, 
Selumetinib, Docetaxel, AZD9291, MEDI4736
NCT02664935 2015 Recruiting
Phase 2 Solid Tumors or Lymphomas -
Afatinib, Binimetinib, Crizotinib, Dabrafenib, 
Dasatinib, Defactinib, AZD4547, Nivolumab, 
Osimertinib, Palbociclib, GSK2636771, 
Sunitinib Malate, Taselisib, Trametinib, 
Trastuzumab Emtansine, Vismodegib
NCT02465060 2015 Recruiting
Phase 2 Advanced Solid Tumors Olaparib (AZD2281) AZD1775, AZD2014 NCT02576444 2015 Recruiting
PKC pan-PKC
AEB-071 Sotrastaurin Novartis n.k. Phase 1b/2
CD79-mutant or ABC Subtype Diffuse Large B-Cell 
Lymphoma
Everolimus NCT01854606 2013 Ongoing
Phase 1b Metastatic Uveal Melanoma BYL719 NCT02273219 2014 Recruiting
PKCβ LY317615 Enzastaurin Eli Lilly n.k. Phase 3 Prevention of Relapse in Lymphoma Placebo NCT00332202 2006 Completed












inhibitors, GDC-0068 enhanced the antitumor activity of chemotherapeutic agents (Lin et al. 2013). In 
preclinical and clinical settings, compensatory feedback activation of ERK and HER3 was observed 
(Yan et al. 2013; Tao et al. 2014). The phase 1 trial included 21 patients with advanced solid tumors 
(Tabernero et al. 2011). Platelet-rich plasma (as a surrogate) and tumor tissue were used to assess 
pharmacodynamics. Akt inhibition was dose-dependent. As a consequence of Akt inhibition, insulin 
levels increased up to 1000 fold. The major adverse events included hyperglycemia, asthenia, nausea, 
and loss of appetite. No objective responses were observed. A recent phase 2 trial has assessed GDC-
0068 in 253 patients with castration-resistant prostate cancer after chemotherapy with docetaxel, a 
taxane derivative. This was a randomized trial with three arms: two different doses of GDC-0068 or 
placebo in combination with the CYP17 inhibitor abiraterone. There was a trend towards better overall 
survival in the GDC-0068 arm. Patients with loss of PTEN seemed to benefit more. This may be of 
importance since more than 20% of prostate cancers have biallelic loss of PTEN (Phin et al. 2013).  
 
GSK2110183 (Afuresertib) is an oral ATP-competitive pan-Akt inhibitor. 73 patients with advanced 
solid tumors were treated in the phase 1 trial (Spencer et al. 2015). Common adverse events were nausea 
(20%), diarrhea (16%), dyspepsia (15%), fatigue (15%), anorexia (12%) and gastroesophageal reflux 
disease (11%). One patient suffered from loss of short-term memory. This is particularly interesting 
since the symptom is rare but it has been described in patients under therapy with PI3K inhibitors as 
well. However, no other neurological or neuropsychiatric disorders were observed with this compound. 
The expansion cohort of this trial focused on multiple myeloma. In a group of 32 heavily pre-treated 
patients, the response rate was 19% (6/32). A preclinical study showed enhanced anti-tumor efficacy of 
GSK2110183 in mouse models of KRAS driven pancreatic cancer when combined with trametinib, a 
MEK1/2 inhibitor (Dumble et al. 2014). However, a phase I study reported high toxicity when both 
compounds were continuously dosed. Intermittent dosing schedules may be warranted. A phase 2 trial 
with GSK2110183 in combination with the monoclonal anti-CD20 antibody Ofatumumab is ongoing in 
refractory chronic lymphocytic leukemia (CLL).  
 
The pan-AKT inhibitor GSK2141795 (Uprosertib) in ovarian cancer enhanced cisplatin-induced 
apoptosis in vitro and decreased phospho-PRAS40 also in vivo (Pachl et al. 2013; Cheraghchi-Bashi et 
al. 2015). Based on these results, it was tested with or without platinum in 12 patients with ovary cancer 
(Gungor et al. 2011). The 18F-deoxy-glucose (FDG) uptake decreased in >70% of tumors that were 
visible on the CT scan. No objective responses were observed. The same compound was tested in 
combination with the MEK1/2 inhibitor trametinib (Algazi et al. 2015). This phase 2 trial accrued 48 
patients with advanced melanoma. Although the combination had an acceptable toxicity profile, no 
responses were observed, neither in the NRAS wildtype nor in the NRAS mutant group of patients. 
Efforts have been made to identify biomarkers of response to AKT inhibitors. At least for GSK2141795, 





susceptibility of cells to AKT inhibition (Cheraghchi-Bashi et al. 2015). However, no clinical trial with 
stratification of patients according to the level of mTORC1 activation has been conducted so far.  
AZD5363 is an oral pan-Akt inhibitor that was identified through fragment-based drug discovery 
(FBDD) and shows a favourable PK and toxicity profile (Erlanson et al. 2016; Coleman et al. 2011). 
Assessment of pharmacodynamics in tumor and surrogate tissue demonstrated effective downregulation 
of phospho-Akt in a range of tumors (Elvin et al. 2014). AZD5363 is currently being investigated in a 
series of phase 2 trials (table 1).  
 
Taken together, AKT inhibitors have a clear impact on cancer cell proliferation and survival. They make 
cancer cells more sensitive to DNA damage by radiotherapy or conventional chemotherapy in vitro and 
in vivo. They have demonstrated efficacy in early trials for metastatic cancer. Yet, the level of efficacy 
in the single-agent setting is low and therefore (i) combination therapies and (ii) a selection of patients 
according to their level of AKT activation must be envisaged (Jansen et al. 2016). Nevertheless, the first 
Akt inhibitors are moving into phase 3 trials and hopefully there will be some positive data in the near 
future.  
 
p70S6K inhibition.  LY2584702 tosylate is selective competitive inhibitor of p70S6K and 
demonstrated efficacy in glioblastoma and colon carcinoma xenograft models (Tolcher et al. 2014). 34 
patients with advanced solid tumors were enrolled in a phase 1 trial (Tolcher et al. 2014). Repetitive 
skin biopsies were taken as a surrogate tissue for the assessment of phospho-S6 suppression. More than 
half of the patients had decreased expression of phospho-S6 by immunohistochemistry, indicating that 
the drug was able to downregulate p70S6K activity. Dose-limiting toxicities included vomiting, 
increased lipase, nausea, hypophosphatemia, fatigue and pancreatitis. Although the compound 
suppressed p70S6 activity, no objective response was observed. A phase 1b trial investigated the same 
compound in combination with erlotinib or everolimus (Hollebecque et al. 2014). The 
LY2584702/erlotinib combination was not well tolerated. Dose-limiting toxicities included vomiting, 
hypophosphatemia, pulmonary embolism and decreased clotting factor V. The observed coagulation 
disorder was surprising since all three compounds did not show signs of coagulopathies when used as 
single agents. No formal DLTs were observed in the LY2584702/everolimus combination arm. 
However, no objective response was observed in either arm.  
 
Due to toxicity concerns and an apparent lack of activity, it is unclear whether p70S6 inhibitors in 
combination with MAPK or mTOR targeting agents will be developed further. Some more recent trials 
have focused on the inhibition of p70S6 in the setting of multi-AGC kinase blockade (see below). 
 
PKC. Enzastaurin (LY317615) is an inhibitor of PKC, a component of the B cell receptor signalling 





Akt, GSK3β and p70S6K (Graff et al. 2005). It decreases tumor proliferation (Moreau et al. 2007; Song 
et al. n.d.) and increases apoptosis in a 4E-BP1-dependent manner in glioma and colon cancer cells 
(Dumstorf et al. 2010). It showed preliminary efficacy in a range of phase 1 and 2 trials in the setting of 
haematological malignancies (Morschhauser et al. 2008; Hainsworth et al. 2016; Schwartzberg et al. 
2014; Ghobrial et al. 2012; Querfeld et al. 2011; Robertson et al. 2007). The phase 3 PRELUDE trial 
has investigated enzastaurin as a maintenance therapy following R-CHOP (rituximab, 
cyclophosphamide, doxorubicine, vincristine, prednisone) therapy of diffuse large B cell lymphoma 
(DLBCL). The primary endpoint was disease-free survival (DFS). The hazard ratio (HR) of the primary 
endpoint was 0.92. This was not significant. A phase 3 trial in high-risk DLBCL patients yielded the 
same (negative) result (Crump et al. 2016). Another phase 3 trial investigated enzastaurin in recurrent 
glioblastoma in comparison to lomustine, an alkylating agent. The primary endpoint of this trial was 
progression-free survival (PFS). No benefit of enzastaurin was noted.  
 
PRKCI gene amplification is a frequent reason for the overexpression of PKCɩ in squamous cell cancer 
of the lung (Regala et al. 2005), serous ovarian cancer (Eder et al. 2005; Kojima et al. 2008; Zhang et 
al. 2006) and oesophageal (Yang et al. 2008) cancer. The gold compound aurothiomalate, which is an 
FDA-approved treatment for rheumatoid arthritis, inhibits PKCɩ signalling and suppresses cell growth 
in the four major subtypes of lung cancer in vitro (Stallings-Mann et al. 2006; Regala et al. 2008).  A 
phase 1 trial evaluated aurothiomalate in 15 patients with non-small cell lung cancer (NSCLC) as well 
as in ovarian and pancreatic cancer (Mansfield et al. 2013). Adverse events included rather mild 
cytopenia and electrolyte disturbances (hypokalemia). No objective response was detected. Since the 
level of PKCɩ suppression was not monitored in this trial, we do not know whether this lack of efficacy 
is due to subtherapeutic dosing or the biological irrelevance of targeting PKCɩ in this population.  
 
AEB071 (sotrastaurin) is a selective oral PKC inhibitor. It blocks both classical (α, ) and novel (, , 
, ) PKC isoforms (Evenou et al. 2009; Naylor et al. 2011). In a phase 1 trial, 118 patients with uveal 
melanoma were treated. Adverse events included nausea (68%), dysgeusia (58%), constipation (48%), 
vomiting (42%), diarrhea (36%), abnormal coloration of the urine (35%) and asthenia (26%). The in 
vivo activity was monitored by assessment of the PKC substrate phosphorylated myristoylated alanine-
rich C kinase substrate (pMARCKS). pMARCKS was reduced by 40-90% after two weeks of therapy. 
However, pMARCKS downregulation did not correlate with response. Out of 118 patients, there was 
only one objective response. In a recent study, AEB071 was combined with either CGM097 (a p53-
MDM2 inhibitor) or RAD001 (a mTORC1 inhibitor) and inhibited the growth of a large panel of patient-
derived xenografts of uveal melanoma (Carita et al. 2016). AEB071 is being assessed in the same patient 
population in combination with binimetinib (a MEK inhibitor) or BYL719 (a PI3K inhibitor) (Carvajal 







In summary, convincing data that PKC inhibitors are effective clinical anti-cancer agents is still missing 
despite frequent alterations of the corresponding gene in various cancers. It remains to be determined 
whether there is a molecularly defined population of cancer patients that draw meaningful benefit from 
the blockade of PKC isoforms.  
 
Multi-AGC inhibitors. The inhibition of PI3K-mTOR signalling through clinically approved, mTOR 
directed drugs, leads to the activation of a feedback loop that upregulates AKT and upstream (receptor) 
tyrosine kinases (Rodrik-Outmezguine et al. 2011; Carita et al. 2016; Soares et al. 2015; O’Brien et al. 
2014; Britschgi et al. 2012). This may be avoided by a dual blockade of p70S6K and AKT or multiple 
blockade of AGC kinases.  
 
AT13148 is a first-in-class oral multi-AGC kinase inhibitor. It targets Akt, p70S6K, PKA and ROCK1/2 
(Yap et al. 2012). Preclinical data showed antitumor activity gastric cancer cells (Xi et al. 2016) and 
reduction of metastasis in vitro and in vivo in melanoma cells (Sadok et al. 2015). The first-in-man trial 
enrolled 14 patients with advanced solid tumors (Kumar et al. 2014). Tumor tissue as well as platelet-
rich plasma and hair follicles were used to assess pharmacodynamic endpoints. Only the data for the 
low dose levels up to 20mg have been published. No downregulation of Akt and no adverse events were 
observed so far. The trial is ongoing.  
 
M2698 (previously MSC2363318A) is a potent p70S6K, Akt1 and Akt3 inhibitor that crosses the blood-
brain barriers in rodents (Machl et al. 2016). 15 patients with advanced solid tumors have been treated 
so far in a phase 1 trial. One dose-limiting toxicity (a grade 3 lipase increase) was observed (Janku et al. 
2014). There is no full publication of this trial yet and further toxicity and efficacy data are expected. 
Taken together, there is yet insufficient data to draw conclusions on the potential of multi-AGC kinase 
inhibitors in the field of clinical cancer therapy. The ongoing trials will hopefully shed a light on the 











VI. Aims of the thesis 
 
 
The aims of my thesis were threefold. 
 
Firstly, we aimed to decipher the role, the inter-connections and the mechanisms of regulation of 
Podoplanin with any druggable targets from patients biopsies and in vitro. 
 
Secondly, we aimed to evaluate the efficacy of a combined treatment with an clinical mTOR inhibitor 
and a targeted radionuclide in a pancreatic neuroendocrine tumor mouse model. 
 
Thirdly, we intended to investigate a novel combined PI3K-mTOR inhibitor pharmacodynamic 





VII. Podoplanin regulates EGFR-driven Akt activation and 










Collective invasion is one way for cancer cells to disseminate effectively to distant organs and is 
essential for tumor progression. Podoplanin (PDPN), a highly O-glycosylated cell membrane protein, is 
a marker for collective invasion at the invasive front in several malignancies. PDPN is known to interact 
with some ECM proteins and have multiple roles in the immune compartment but how PDPN is 
regulated is poorly understood.  
 
Material and methods 
Using patient fresh biopsies from head & neck, lung and cervix squamous cell carcinoma (SCC) cohorts, 
we isolated by laser capture microdissection the invasive margin of the tumor for further analysis. In 
addition we compared them with three corresponding SCC established cell lines, A431, H226 and Cal 
27, to test PDPN-mediated invasiveness in different 3D in vitro experiments.  
 
Results 
PDPN and EGFR are overexpressed in our tumor cohorts and in vitro system and correlate inversely 
with overall survival. PDPN is responsible for EGFR-induced cell protrusions and cell invasion in 3D 
environment. Moreover, PDPN regulates the activation of two of the downstream key element of EGFR 
pathway, Akt and STAT3 but independently of  EGFR. Additionally, Erk 1/2 is not regulated by PDPN. 
Finally, PDPN downregulation sensitizes to EGFRi-induced apoptosis and acquired resistance in the 
three different squamous carcinoma cell lines.  
 
Conclusion 
The EGFR-dependent activation of Akt and STAT3 is regulated by PDPN. Our results support a role 
for PDPN as a potential biomarker of resistance to EGFR tyrosine kinase inhibitors (TKIs) already 








Squamous cell carcinoma (SCC) is a malignancy arising within the stratified epithelium of the upper 
aerodigestive tract, skin, lung, esophagus, pancreas as well as anus and cervix. It is the most common 
malignancy of head and neck mucosa and the second most common skin cancer (Ferlay et al. 2010). 
The malignancies are characterized by phenotypic, biological, etiological and clinical heterogeneity. 
With exception of HPV status, there are no clinically relevant risk factors or biomarkers. Over the last 
three decades, the 5-year survival rates remain low due to treatment-induced resistance and distant 
metastasis  (Hedberg et al. 2016; Leemans et al. 2011). Therefore, it is important to understand the 
resistance and metastasis mechanisms of SSC. 
 
EGFR is overexpressed in more than 90% of  head & neck squamous cell carcinoma (HNSCCs)(Sacco 
& Cohen 2015) and present in more than 60% of lung SCC (da Cunha Santos et al. 2005). Beside the 
FDA approved monoclonal antibody cetuximab, several tyrosine kinase inhibitors (TKI) have been 
investigated. As monotherapy, Gefitinib has limited activity compared with standard chemotherapy in 
head and neck (Argiris et al. 2013) but is already approved by the FDA for non-small cell lung cancer. 
Another TKI, Afatinib, became the first oral TKI to demonstrate efficacy and improvement in patient-
reported outcomes in a phase III trial (Machiels et al. 2015). De novo or acquired resistance to EGFR-
targeted therapy is a major hurdle for cancer treatment. For instance, secondary somatic mutation of 
EGFR, T790M, was reported in relapsed NSCLC (Kobayashi et al. 2005; Pao et al. 2005). The EGFR 
pathway has several downstream element like Akt, Pi3K, RAS, MAPK or the member of the JAK/STAT 
family (Tebbutt et al. 2013). In addition, the pair EGFR – STAT3 has been shown to be extremely active 
in malignancies (Lee et al. 2014). 
 
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling 
pathway is one of the main growth regulatory pathways in both normal cells and cancer (Mayer & 
Arteaga 2016; Laplante et al. 2012). Multiple genetic events have been described that lead to activation 
of the PI3K/AKT/mTOR pathway in cancer (Thorpe et al. 2015; Guri & Hall 2016). In different 
integrated genomic and molecular characterization, the Cancer Genome Atlas Research Network 
showed that the HPV-negative SSC malignancies were highly mutated for this pathway, either with 
activating mutation of PIK3CA or inactivating mutations of PTEN (Cancer Genome Atlas Research 
Network et al. 2017; Hammerman et al. 2012). 
 
Podoplanin (PDPN), also known as T1α, aggrus and gp36, is a type-I transmembrane protein composed 
of 162 amino acids, whose expression is widely distributed in different tissues including kidney, lung, 
heart and skeletal muscle (Breiteneder-Geleff et al. 1997; Wicki & Christofori 2007). PDPN emerged 





from blood vessel endothelium  (Breiteneder-Geleff et al. 1999). Podoplanin (PDPN) is expressed at the 
invasive front of several malignancies like squamous cell carcinomas (Wicki & Christofori 2007), 
tumors of the central nervous systems, germ cell tumors (Sonne et al. 2006), mesotheliomas (Kimura & 
Kimura 2005), vascular tumors (Naqvi et al. 2008) and bone tumors (Ariizumi et al. 2010). 
 
How PDPN actually promotes tumorigenesis is poorly understood. Three of basic amino acids of its 
nine amino acid intracellular tail has been shown to interact with proteins of the ERM family (ezrin, 
radixin and moesin) (Yonemura et al. 1998; Martin-Villar et al. 2006; Wicki et al. 2006). Other 
interactions or direct binding have been shown with Tetraspanin CD9 (Nakazawa et al. 2008), Galectin 
8 (Cueni & Detmar 2009), Heat Shock Protein A9 (Tsuneki et al. 2013) and CD44 (Martin-Villar et al. 
2010). The interaction between the third platelet aggregator domain (PLAG3) of the extracellular 
domain of PDPN and platelet CLEC-2 (Nagae et al. 2014; Kato et al. 2003; Herzog et al. 2013) is critical 
for the separation of the lymphatic compartment from the blood vascular system. It can also protect 
PDPN positive cancer cell in the blood stream from the immune surveillance by covering them with 
platelets (Erpenbeck & Schön 2010). 
 
We previously showed that PDPN is expressed in the leading cells at the collective front bypassing EMT 
in vitro and in vivo. Recently, we showed that PDPN can be induced by single or combined treatment 
with interferon interferon  (IFN ), transforming growth factor  (TGF) and/or tumor necrosis factor  
(TNF) (Kunital et al, in preparation). Here we report that EGFR resistance to EGFR inhibitor is 
mediated by PDPN in vivo, using 3 cell lines from skin, lung and head & neck SCCs. In this setting, 
EGFR-dependant Akt activation is also effective only in presence of PDPN, These findings are further 
confirmed by patient biopsies from lung, head & neck and cervical tumors. Together, PDPN could be a 







Material & Methods 
Cell lines 
H226 and Cal 27 were purchased from the ATCC collection. A431 was grown in Dulbecco's modified 
Eagle medium (DMEM; Sigma), and H226 was cultured in RPMI 1640 (Sigma) with 10% fetal bovine 
serum (FBS), 100 U/mL penicillin and 100 mg/mL streptomycin (Sigma), at 37°C saturated with 5% 
CO2 in a humid atmosphere. 
 
Lentivirus production, infection and selection. 
Lentivirus were produced, infected and selected using shPDPN pTRIPZ-based vectors 
(V3THS_401024, Dharmacon GE, USA) and trans-lentiviral packaging shRNA packaging kit 
(Dharmacon GE, USA) according to manufacturer’s instruction. The cells were then sorted by an Aria 
(BD, USA) according to their RFP fluorescence in single clones in a 96 well plate with 20% FCS and 
20% of  conditioned medium. PDPN knockdown was confirmed subsequently by qRT-PCR and FACS. 




PQR309, GDC-0980 were a generous gift from Piqur Therapeutics AG (Basel, Switzerland). MK2206 
was provided by Brian Hemmings. Erlotinib and Afatinib were purchased from Selleck Chemical 




Whole cell lysates from cultured cells were prepared, separated using SDS-PAGE and immunoblotted. 
The membranes were incubated with antibodies against PDPN, phospho-Akt, Akt and GAPDH, all 
purchased from Cell Signaling Technology (USA) and diluted according to recommended  
manufacturer’s recommendations. 
 
Cell migration and matrigel assays 
A wound healing assay was performed by use of the Ibidi chambers (Ibidi GmbH, Switzerland). After 
serum starvation overnight, the cell migration was visualized and recorded (Olympus IX61) for 30 hours 
at 37°C.  
Grow Factor Reduced (GFR) Matrigel (Corning, USA) was melted at 4°C and applied on the bottom of 





fresh medium was added with or without EGF (100ng/ml, generous gift from Brian Hemmings lab) for 
16 hours. Pictures were taken by an Olympus IX61 (Olympus, Japan). 
 
Histological analysis of primary human tumor sections 
Tumor biopsies were freshly frozen in isopentan at -80°C, fixed 60 min in 4% paraformaldehyde, 
embedded in OCT, and cut into 8 µm sections on a cryostat. The plates were blocked for 1 hour at RT 
in PBS + 4% BSA and incubated O.N. at +4°C with primary antibody. The plates were washed 3x5min 
with PBS and incubated for 30 min at RT in a dark room with the secondary antibodies coupled with 
Alexa Fluor 488 or 555 (Invitrogen) and diluted 1:200 in PBS + 4% BSA. After washing, the fluorescent 
nuclear stain 4’,6’-diamidino-2-phenylindole dihydrochloride (DAPI, Sigma Aldrich) was added and 
the plates incubated for 2 min at RT. Immunofluorescence microscopy was performed on a Olympus 
BX63. 
Primary antibodies were Podoplanin (Angobio, clone NZ-1), pSTAT3 (Cell Signaling Technology, 
#9145). 
 
Laser capture microdissection 
Tumor biopsies were freshly frozen in isopentan at -80°C, embedded in OCT, and cut into 8 µm sections 
on a cryostat onto a LCM-specific MembraneSlide 1.0 PEN NF (Zeiss). Tumor slides were stained with 
Arcturus HistoGene LCM Frozen Section Staining Kit (Applied Biosystems) according to 
manufacturer’s instruction. Laser capture microdissection was performed on LSM Palm and tumor 
tissue was lifted up onto RNAse-free AdhesiveCap 500 opaque (Zeiss). RNA was then extracted using 
Arcturus PicoPure RNA Isolation Kit (Applied Biosystems). 
 
Quantitative RT-PCR and PCR arrays 
Whole slide total RNA was prepared using Trizol (Invitrogen), reverse transcribed with Maxima 
Reverse Transcriptase (Thermoscientific, USA), and quantified by PCR using SYBR green PCR 
MasterMix (Applied Biosystems, Rotkreuz, Switzerland) and the following primers’ pairs: human 
PDPN, 5’-AAA TGT CGG GAA GGT ACT CG-3’ (F) and 5’-AGG GCA CAG AGT CAG AAA CG-
3’ (R); human HPRT1, 5’-TGA CCT TGA TTT ATT TTG CAT ACC-3’ (F) and 5’-CGA GCA AGA 
CGT TCA GTC CT-3’ (R). Human HPRT1 primers were used for normalization. PCR assays were 
performed in triplicate, and fold induction was calculated against control-treated cell lines using the 
comparative Ct method (ΔΔCt). 
After microdissection, RNA was first preamplified using RT² PreAMP cDNA Synthesis Kit and 









Whole slide were lysed with Pathscan sandwich elisa lysis buffer (Cell Signaling Technology, USA)  
freshly added with Protease Inhibitor Cocktail (Cell Signaling Technology, USA). Protein lysates were 
loaded onto PathScan Akt Signaling Antibody Array Kit (Cell Signaling Technology, USA). Protein 
array near infrared detection were done on Odissey CLx  (Li-cor, USA). 
 
Establishment of the resistant cell line 
A431 cells were treated with an EGFR inhibitor during at least 1 month with 0.1μM the first week, 
0.5μM the second and 1μM for the subsequent weeks. 
 
Long-term proliferation assay  
A431, Cal 27 or H226 cells were seeded into 6-well plates at 500 cells per well in the presence/absence 
of  inhibitor (0.5 or 1 μM) for 21 days or until 100% confluency of the controls. Fresh medium was 
added 3 times per week. The colonies were fixed with PFA and stained with crystal violet for 30min, 
followed by 3 times of rinsing with PBS, air-drying and photography of the entire plates. Samples were 
prepared in triplicates. 
In another experiment, 10’000 cells for A431 and Cal 27 and 15’000 cells for H226 per well were seeded 
into a 6-well plate 16 hours prior to treatment. Then cells were treated with fresh medium 3x per week 
during 2 to 14 days. At each time point, the cells were rinsed, dissociated using trypsin, diluted according 




Cells were trypsinized, washed with FACS buffer and incubated with Ki67, AnnexinV (BD Bioscience) 
and/or the indicated primary and secondary antibodies for 30 minutes on ice. Dead cells were excluded 
by staining with UV Live/Dead (ThermoFisher Scientific) and gating on the negative population. After 
fixation with IC Fixation Buffer (eBioscience), cells were acquired on a LSR II Fortessa and analyzed 






CRISPR-mediated gene editing 
Guide RNAs were designed using E-CRISPR(Heigwer et al. 2014) and respective oligos cloned into the 
pX458 vector according to protocol (pSpCas9(BB)-2A-GFP (PX458). This vector was a gift from Feng 
Zhang, Addgene plasmid # 48138)(Arowolo et al. 2011). 
Target cells were transiently transfected and GFP+ cells single cell sorted 48h later. Growing clones 
were analyzed for Podoplanin expression by flow cytometry and negative clones pooled. 
 
Spheroid assay 
A431 RFP-negative cells were first pre-stained with DII (Molecular Probes, USA) according to 
manufacturer’s instructions .Cells were filtered through a cell strainer and then 1250 cells in 40 μL in 
an GravityPLUS spheroids plate (Insphero Sàrl, Switzerland) according to manufacturer’s instructions.  
 
Statistical analysis 
Data were analyzed using Graphpad Prism v.6 (Graphpad Software Inc., San Diego, CA) and presented 
as means ± SEM. Mann-Whitney U-test or one-way ANOVA followed by Tukey-Kramer multiple 








PDPN is upregulated in squamous cell carcinoma tumors. 
First, we wanted to confirm that the patient biopsies from our cohort were expressing Podoplanin. We 
stained tumors from head & neck, lung and cervical biopsies and compared them to a positive control, 
an adjacent lymphatic vessel (Figure VII-1A). We also controlled that the staining was at the membrane 
area by co-staining with cytokeratin 14, a membrane and invasion marker (Suppl. Figure VII-1A). The 
podoplanin expressing tumors were in majority only in head & neck cohort (21/26, 84%) whereas its 
content was only 41% in lung and 27% in cervix (Figure VII-1B).  
When we checked on a bigger cohort freely available, the Atlas Genome Cohort, the overall survival 
was better in the top 20% of high PDPN expression compared to the low 20% (p=0.017) in head & neck 
(Figure VII-1D), whereas only a non-significant trend in lung SSC (Suppl. Figure VII-1C). To validate 
our observation from the clinic in an in vitro experimental model, we checked by FACS the amount of 
PDPN of three SSC cell lines, their inducible knockdown clones (Figure VII-1D) and their knockout 
clones using the CRISPR-Cas9 method (Suppl. Figure VII-1B). The knockout had no measurable 
expression of PDPN whereas the shPDPN clones of A431, H226 and Cal 27 had 77%, 45% and 16% of 
reduction respectively. 
 
PDPN is responsible for EGFR-induced cell motility. 
We tested then the invasiveness of PDPN expressing cell lines. When A431 cells are cultured in growth 
factor-reduced matrigel, the membrane protrusion is dramatically delayed but rapidly rescued by EGF 
(Figure VII- 2A). Interestingly, when A431 cells are cultured in hanging drop, the size of spheroid-like 
mass is ~3.5-fold smaller in PDPN-depleted cells after 72h (p<0.001, Figure VII-2B). This PDPN-
dependent phenotypic change in 3D could also be replicated by growing on matrigel. In the control 
sphere expressing PDPN after 5 days, the daughter cells (Suppl. Figure VII-2A, black arrow) start to 
disseminate from the sphere. However, the PDPN-depleted sphere shows smooth edge and proliferative 
pattern. Both spheres are maintained up to 21 days with gradually enhanced distinction of phenotypes, 
which the disseminated cells are capable of clustering to form new sphere and re-disseminate in a PDPN-
dependent manner ((Suppl. Figure VII-2A, blue arrow). In fact, although we could occasionally observe 
a migratory potential in PDPN-depleted sphere, the outgrowing clusters often undergo apoptosis in 
spheroids (Suppl. Figure VII-2B) or in vessel-like structures (Suppl. Figure VII-2C).  
In a wound healing assay, A431 cell migration stimulated by EGF is decreased when PDPN is knocked 
down, and incubation with Akt1/2 inhibitor MK-2206 also suppresses cell motility in presence of EGF 
(Figure VII-2C). PDPN-depleted A431 cells grown on matrigel form similar luminal structures as 
treated with inhibitors targeting PI3K/Akt/mTOR pathway (Suppl. Figure VII-2D). The invasive 





extracellular matrix, because PDPN-depleted A431 cells dramatically lose the capacity of degrading 
gelatin within 72h (Suppl. Figure VII-2E). 
 
Cellular localization of EGFR-activated Akt is regulated by PDPN 
We then wanted to assess whether downstream element of EGFR were activated. The whole slice lysis 
of patient tumors showed an increased phosphorylation of PDPN positive SSC tumors of the lung and 
head and neck (p<0.01, Figure VII-3A). RNA is more stable compared to phospho-protein so we 
performed a laser capture microdissection of the region of interests (ROI) in the same patient biopsies 
and EGFR was upregulated by 2.3 fold in the tumors expressing PDPN (p=0.015, Figure VII-3B).  
Moreover, in response to EGF, the cells expressing PDPN showed membrane protrusions, while in 
absence of PDPN, the filopodia-like structures are significantly diminished (Figure VII-3C). The 
localization of phosphorylated Akt is remarkably different upon PDPN depletion; there is massive 
accumulation of phosphorylated Akt specifically located at membrane protrusions where the actin 
polymerization is greatly enhanced (Figure VII-3D). When PDPN is depleted, upon stimulation with 
either insulin or IGF, induced Akt phosphorylation could also be observed but restricted to intercellular 
junctions (Figure VII-3D). We blotted the phospho-Akt expression when activated with EGF for 16 hour 
upon serum starvation and it can re-activate p-Akt in presence of PDPN but less in absence of PDPN.  
In addition, the erlotinib resistant clones showed an increased activation of Akt when starved or activated 
with EGF (Figure VII-3E). Lastly, we observed that PDPN can be rapidly cleaved upon serum 
starvation, which could be inhibited in presence of EGF stimulation (Suppl. Figure VII-3A). This data 
showed that EGFR signaling may functionally regulate PDPN through supporting its correct folding 
and/or stability.  
 
EGFR-dependent activation of STAT3 is regulated by PDPN 
To further confirm the activation of the EGFR pathway, we looked at another canonical downstream 
element, STAT3. In our head & neck und lung cohort, 63% of the PDPN expressing tumors were co-
expressing phospho-STAT3 whereas only 11% of the non-PDPN expressing tumors were positive 
(Figure VII-4A). The co-expression of phosphor-STAT3 was within the invasive strand, a finger-like 
structure invading its surrounding like in Figure VII-4B. These features could be recapitulated when 
A431 cell were grown on Matrigel but only in presence of EGF in PDPN-expressing cells. (Figure VII-
4C). These data further confirmed the PDPN-driven EGFR activation with phospho-STAT3 in 






PDPN upregulation is associated with EGFRi-induced acquired resistance and apoptosis in squamous 
carcinoma cell lines 
Interestingly, we observed that PDPN-positive cells were less sensitive to EGFR inhibition than their 
respective knockout or knockdown clones. Our three cell lines are negative for the EGFR T790M 
mutation. We assessed these properties in a resistance assay. The shPDPN clones were significantly 
more resistant to Erlotinib and Afatinib for A431 and H226 compared to the untreated cells, whereas 
Cal27 was very sensitive with or without PDPN (Figure VII-5A). The knockdown clones showed a 
similar or slightly increased effect for Cal-27 on day 14 (Figure VII-5B). We analyzed the PDPN protein 
expression in these wild type resistant clones and PDPN was increased by 1.65, 1.45 and 1.88 fold for 
A431, H226 and Cal 27 respectively (Figure VII-5C). When analyzed with FACS, these cells show that  
PDPN downregulation sensitizes to EGFRi-induced apoptosis by elevating cleaved caspase 3 (Figure 
VII-6A) and consistently elevated amount of cells in early (Figure VII-6C) as well in late apoptosis 
(Figure VII-6D). Finally, we also observed similar reaction to other classes of inhibitors such as a 
combined PI3K inhibitor PQR-309 and the PI3Ka/d inhibitor GDC-0941 in a different resistance assay 








These data potentially indicates that PDPN-dependent cell proliferation, migration and invasion are 
substantially promoted by a 3D environment; secondly, PDPN potentially regulates cell fitness in 
stressed conditions such as nutrient restriction and lastly, PDPN may potentially contribute to resistance 
to unfavorable environments during cell proliferation. It has been noticed that the cancer cells in the 
core of spheroid are capable of continuous proliferation in a PI3K/Akt-dependent manner, although the 
nutrient supply is restricted.  
 
Consistent with those findings, treating these spheroids with PI3K/Akt/mTOR inhibitors induces notable 
apoptosis in the center of the spheroid, while the cancer cells at the edge that access the environmental 
nutrients and associate with reactivated PI3K/Akt signaling will still survive (Muranen et al. 2012), 
indicating that this signaling axis contributes to unresponsiveness to drugs potentially targeting the 
PI3K/Akt signalosomes. 
 
Our results show that PDPN expressing cancer cells  have a survival advantage toward EGFR inhibition. 
A similar phenomenon was observed in the clinic, especially in the lung malignancies where upon EGFR 
inhibition by TKI or antibody, adenocarcinoma transition to squamous cell carcinoma (AST, reviewed 
in (Hou et al. 2016)). This mechanism may be responsible for drug resistance and it would be interesting 
to check the PDPN status of these evolving tumors. 
 
The quite low level of PDPN-expressing lung and cervix tumor may be partially caused by the tumor 
heterogeneity, as we resect only a small fraction of the tumor that may not include the invasive front. 
Another explanation for the lung cohort is the difficulty of assessing precisely the SSC subtype and the 
transition from SSC to adenocarcinoma in these malignancies. 
 
Using the K14-HPV16 mouse model of invasive uterine cervical SCC (Giraudo et al. 2004), Kunita and 
colleague had similar findings in a recent paper (Kunita et al. 2018). They showed that inflammatory 
cytokines, including phospho-STAT3, co-localized with PDPN-expressing cells in the invasive areas of 
cervix of mice and of cervix SCC in patients. In our study, we did not investigate the other related 
cytokines. 
 
Interestingly, the efficiency of shPDPN in its reduction of PDPN was correlated with the resistance 
assay. A431 had the better PDPN reduction and the bigger difference in proliferation compared to Cal 







Together, these data indicate that PDPN is interfering with a druggable target and a well-known 
signaling pathway. It would be interesting to discover the real underlying mechanism of these 
interactions. Hence, a screening of resistant SSC patient prior to their treatment with EGFR inhibitors 
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Figure VII-1 : Podoplanin is expressed at the invasive front of SSC. 
A, Immunoflurescence staining of H&N (upper left), lung (upper right), cervix (lower left) and a positive 
control, a lymphatic vessel (lower right). Red is PDPN, blue is DAPI. Scale bar is 60um. B, Proportion 
of Podoplanin positive tumors from each cohort with percentage on top of each bar. C, Histograms of 
FACS staining of A431, H226 and Cal27 and their respective shPDPN conditional knockdown clones. 
Logarithmic scale on the x-axis. D, Overall survival of the head & neck SCC TCGA cohort in days. Red 








Figure VII-2 : PDPN is responsible for EGFR-induced motility 
A, Single A431 cells forming spheroids after 5 days on growth factor reduced Matrigel with or without 
EGF in medium (left or right) for WT (upper) or shPDPN cells (lower). B, Spheroids in hanging drops 
after 2 and 72 hours. Lower graph is relative spheroid size to 2h time point. Mean + SEM, 
****p<0.0001. C, Wound healing assay with A431 cells with EGF and EGF + MK2206 Akt inhibitor 








Figure VII-3 : EGFR-dependent activation of Akt is regulated by PDPN 
A, Graph of the phospho-protein level of Akt at the serine 473 site for PDPN+ (n=6) and PDPN- (n=10) 
tumor biopsies. RFU= relative fluorescent units, **P<0.01.  B, Table with the EGFR fold change in 
PDPN+ tumors compared to PDPN- (upper). The ROI stained before laser capture microdissection (left) 
and after (right). Scale bar = 60um. C, A431 cells grown on Matrigel in absence or presence of Matrigel 
after 14 days. Slides are stained for actin. Yellow arrows indicate the philopodia-like structures. D, 
Immunofluorescence pictures of phospho-Akt Serine 473 site (green, left) and actin (red, right). Yellow 
arrows indicate the membrane protrusion. E, Immunoblotting for control (FCS), starved and EGF treated 
cells. Proteins are PDPN, total Akt, phosphor-Akt Serine 473 and GAPDH. ErloR mean erlotinib 








Figure VII-4 : EGFR-dependent activation of STAT3 is regulated by PDPN 
A, Table with total number and percentage of tumors in each category: PDPN positive, negative, 
proportion of phospho-STAT3 positive in PDPN positive and negative tumors. B, Immunofluorescent 
cross-section of an invasive strand in a human biopsy. Red, PDPN; Green, phospho-STAT3; blue, DAPI. 
Scale bar = 60um. C, Immunofluorescent pictures of A431 cells on Matrigel with or without EGF in 








Figure VII-5 : PDPN upregulation is associated with EGFR-induced acquired resistance 
Graphs of A431, H226 and Cal 27 cell lines as a percentage of the untreated controls comparing wild 
type cells with A, shPDPN clones and B, CRISPR/Cas9 knockout. In each graph, the two upper lines 
are WT. C, Histograms of FACS staining for WT, erlotinib and afatinib resistant clones. Logarithmic 








Figure VII-6 : PDPN upregulation is associated with EGFR-induced apoptosis 
FACS staining of resistant cell from figure VII-5. Percentage of cells positive for A, cleaved caspase 3, 









Suppl. Figure VII-1  
A, Immunoflurescence co-staining of H&N tumors (right) with PDPN (upper left) and membrane 
marker K14 (lower left). Red is PDPN, green is K14 and blue is DAPI. B, Histograms of FACS staining 
for A431, H226 and Cal27 and their respective CRISPR/Cas9 knockout clones (n=2 or 3). C, Overall 
survival of the lung SCC TCGA cohort in days. Red is low PDPN expressing patients, black is high 







Suppl. Figure VII-2   
A, Bright-field microscopy of A431 cells protrusion on Matrigel in presence or absence of PDPN after 
5 and 14 days. Blue arrow and black arrows indicate new spheres.  B,  Bright-field microscopy of A431 
cells undergoing apoptosis in bright field (BF) and corresponding red fluorescence with DII die (RFP). 
C, A31 cells forming stabilized tubule-like structures after 21 days on Matrigel with PDPN and apoptotic 
without PDPN. D, luminar-like structure in absence of PDPN in A431 cells on Matrigel stained with 
DII. E, zymography of cells with bright field (upper) and fluorescent picture of GFP-labeled gelatin 







Suppl. Figure VII-3  
A, Immunoblotting of shPDPN with or without doxycycline (knockdown). The second line represents 
the time of treatment with EGF without serum. The third line, the starvation status. The arrows indicate 







Suppl. Figure VII-4  
A, Bright field picture of a 6-well plate with wt and shPDPN clone. The doses are 0.1 and 1.0 uM, 







VIII. Combined treatment of neuroendocrine tumors with Lu-177-









Purpose: The aim of this study is to evaluate the combined treatment of neuroendocrine tumors with 
PRRT and mTOR inhibitor Everolimus in a preclinical setting. Rip1Tag2 mice develop insulin 
producing neuroendocrine tumors in the pancreas that are known to express GLP-1-receptor and to be 
dependent on mTOR. This makes Rip1Tag2 mice an ideal model to study PRRT with 177Lu-DOTA-
exendin-4 ([Lys40(Ahx-DOTA-177Lu)NH2]-exendin-4) and Everolimus. We investigated the long-
term survival as well as histology and phospho-proteins of the pNET tumors. 
 
Methods and Materials: Rip1Tag2 mice were treated with 177Lu-DOTA-exendin-4 (2MBq day1, 
1MBq day36), Everolimus 5mg/kg daily or every third day and combination of both. n=10 planned. One 
series is carried out over 20 days, a second series over a maximum of 9 months. Besides tumor size and 
survival, AKT/mTOR-pathway, proliferation, apoptosis activity was analyzed. 
 
Results: Preliminary long-term results (5-7 mice/group) showed minor prolonged survival for PRRT 
alone (37.8+/-11.9 days) over control (27.3+/-5.9 days). Everolimus (77.1+/-24.3 days, ) as well as the 
combined treatment (73.0+/-17.1 days) clearly extended survival. 
 
While daily treatment over 20 days with Everolimus lead to reduced tumor weight (41.8+/-40mg; control 
73.4+/-26mg), Everolimus given every third day didn’t alter tumor weight (81.5+/-44mg). Combination 
of Everolimus daily and PRRT showed high synergistic potential (7.8+/-10mg). 
 
Histology showed no alteration in mTOR/AKT-pathway activity through PRRT but reduced activity in 
combination with Everolimus daily. Everolimus given every third day had a paradox effect with a 
tendency to activate mTOR/AKT-pathway. 
 
Conclusion: These results demonstrate efficacy of both treatments alone and the potential of combined 
treatment. Everolimus is only effective when given daily. Intermittent administration of Everolimus isn't 







Neuroendocrine tumors (NETs) are a rare malignancy with increasing incidence (Modlin et al. 2003). 
NETs arise predominantly from the gastrointestinal tract or the pancreas, belong to the less aggressive 
malignancies and may develop no or only mild clinical symptoms over years. Most of the patients are 
diagnosed in an already metastasized stage and only complete surgical removal can cure.  
Well differentiated NETs overexpress the somatostatin receptors at high density (Reubi & Waser 2003) 
as well as glucacon-like peptide 1 receptor (GLP-1R) (Wild et al. 2006) among other specific receptors. 
Peptide receptor radiotherapy (PRRT) with radiolabelled somatostatin analogues, such as 90Y-/177Lu-
DOTATOC or 177Lu-DOTATATE, can be used for the specific targeting of these tumors (Imhof et al. 
2011; Kwekkeboom et al. 2008). According to the last ENETS guidelines, PRRT is recommended as a 
the second line treatment option of metastasized intestinal neuroendocrine tumors with other targeted 
therapies (Pavel et al. 2016). Though PRRT can cause kidney insufficiency and has hematotoxic 
potential, the balance of side effects to treatment effect is favorable (Villard et al. 2012; Kwekkeboom 
et al. 2008). Therefore there is a rational for combined treatment demonstrating? lower side effects due 
to reduced doses and an additive or synergetic potential effect. Only palliative systemic therapy are used 
in the clinic. Combination therapy, such as 177Lu-DOTATATE and CAPTEM (Claringbold & Turner 
2016),  have the potential to ameliorate these palliative therapies. Previously, we applied successfully 
combined treatment with Vatalanib, an antiangiogenic drug (Wicki et al. 2014). 
 
mTOR inhibitor RAD-001 (Everolimus®) is approved by FDA and EMA for the treatment of 
metastasized NET since the RADIANT trials approved efficacy of Everolimus® (Pavel et al. 2011; Yao 
et al. 2008; Yao et al. 2011). For many NETs, it has been shown that proliferation is dependent on 
mTOR (Johannessen et al. 2005). RAD-001 interferes with the mTOR complex after it bound to the 
intracellular receptor FKBP12 (O’Donnell et al. 2008; Laplante et al. 2012) and possibly has some anti-
angiogenic properties (Lane et al. 2009). Moreover, in vitro data show the radio-sensitizing effect of 
Everolimus (Mauceri et al. 2012; Shinohara et al. 2005), where the PI3K pathway seems to play a pivotal 
role (Manegold et al. 2008; Prevo et al. 2008). 
 
In 2013 and 2014, two papers proposed that Everolimus does not have an additive or synergistic effect 
in combination with PRRT and even promotes metastases in a rat xenograft model of neuroendocrine 
tumor (Pool et al. 2013; Bison et al. 2014). Up to now, such an effect has not been found in clinical 
studies. In the setting of controversial preclinical and clinical data many centers ask patients to stop 
mTOR inhibition before PRRT. The fear of additive side effects, such as low blood count pronounced 






The aim of this study was to evaluate any additive or synergistic effect of combined PRRT and mTOR 
inhibitor treatment and clarify the existing controversies in the literature. Using transgenic Rip1Tag2 
mice, this study was carried out in an immune competent, more physiological and potentially better 










Rip1Tag2 transgenic mice develop insulin producing neuroendocrine tumors in the pancreas in a well 
characterized multistep tumorigenesis (Hanahan 1985). Mice were kept in a C57Bl/6 genetic 
background and breeded as previously described (Wicki et al. 2007). All mice were tested with PCR for 
the Rip1Tag2 defect. Mice were included in the experiment at the age of 11 weeks. All animal 
experiments were performed according to the guidelines and legislation of the Swiss Federal Veterinary 




177Lu-DOTA-exendin-4 was prepared after incubation of 7.5 μg DOTA-exendin-4 (1 mg/mL in water) 
with 80-170 MBq 177LuCl3, at 95°C for 30 min in ammonium acetate buffer (0.4 M, pH 5.0). Quality 
control was performed by reverse phase high performance liquid chromatography (RP-HPLC). The 
radiolabeled peptide solutions were prepared by dilution with 0.9% NaCl containing 0.05% HSA at 
specific activities of 50 MBq/nmol and 100 MBq/nmol, for biodistribution and therapy studies, 
respectively.   
 
Biodistribution studies 
Biodistribution studies of 177Lu-DOTA-exendin-4 (1.1 MBq, 20 pmol) were done in untreated groups 
(n >= 5) of Rip1Tap2 mice, serving as control and Rip1Tag2 mice after pre-treatment with Everolimus 
at 1, 5 or 10 mg/ kg bodyweight. Pre-treatment consisted of oral drug administration over 3, 7 and 10 
days daily. Furthermore biodistribution of 1 MBq 177Lu-DOTA-Exendin-4 were performed after treating 
mice with 5 mg Everolimus daily (E cont) over 10 days and a period of withdraw of 10 days. Another 
group (E pulse) had been analysed after pre-treatment with 5 mg/kg bodyweight Everolimus every third 
day. 4 hours after the injection of 1 MBq 177Lu-DOTA-Exendin-4 in the tail vein, the mice were 
euthanized. Then blood and the following organs were resected : stomach, both kidneys, bowel, 
pancreas, spleen, liver, leg muscle, lung heart, adrenals, bone, pituitary and the tumors. The organs were 
weighed in a precision balance and activity was measured by a beta-counter. 
 
Therapy studies  
Different therapy regimen have been analysed for the efficacy after 10 or 20 days as well. Groups of 
Rip1Tag2 mice included untreated control, Everolimus 5 mg / Kg bodyweight daily (E cont), 
Everolimus  5 mg / Kg bodyweight every third day (E pulse), PRRT with 2.2 MBq 177Lu-DOTA-





combined with the PRRT of 2.2 MBq 177Lu-DOTA-Exendin-4 (Combined). Mice were euthanized, total 
tumor burden (weight) assessed and tumors were analysed for proliferation, apoptosis, microvessel 
density. 
Mice were injected 1.1 MBq or 2.2 mBq of Lu-177-Exendin-4 at a peptide mass of 10 pmol each via 
tail vein injection. 
Everolimus (also known as RAD001) was administered orally after dissolving in 5% glucose at a dose 
of 1 mg/ KG bodyweight, 5 mg/ KG bodyweight or 10 mg/ KG bodyweight. Volumes administered 
were bodyweight adapted (1 ml / 100 g bodyweight). Stock solution of Everolimus was provided by 
Novartis Pharma, Switzerland.  
Furthermore long term survival was examined in groups of 10, including untreated control, Everolimus 
5 mg / Kg bodyweight daily (E cont), 5 mg / KG bodyweight every third day (E pulse), PRRT with 2.2 
MBq 177Lu-DOTA-Exendin-4 at start of treatment and a second injection 1.1 MBq at day 36 (PRRT) as 
well as the combination of Everolimus 5 mg / Kg bodyweight daily and PRRT with the regimen 
mentioned above (Combined). This series was carried out over a maximum of 9 month or until 
predefined endpoints (loss of bodyweight, behavioural impairment, low blood glucose levels) were 
reached as previously described (Bill & Christofori 2016). The termination criteria were based on a 
weight score (+/- 2g = 0, +/- 4g = 2, >= 4g = 3), an activity score (normal activity = score 0; 
wiggling/reduced activity = 2; still/hunchback/poor general condition = 3) and blood glucose levels 
(>2.1 mmol/L = score 0; 1.1–2.0 mmol/L = 1; 0.7–1.0 mmol/L = 2; <0.7 mmol/L = 3) measured using 
the blood glucose meter Contour Next (Bayer). Mice were euthanized when reaching a total score of 6 
or if presenting with score 3 in one of the three criteria. 
 
GPL1-R density 
Untreated control mice and mice treated over 10 days with Everolimus 10 mg / Kg Bodyweight (groups 
of 4 each, with 2 or 3 tumors per mice) were freshly frozen on dry ice for GLP-1-receptor density. Then 
GPL1-R quantification was performed by in vitro receptor autoradiography as previously described 
(Reubi et al. 2010). 
 
Tissue preparation for histology 
For immunofluorescence (IF) staining, organs (pancreas, kidney, adrenal gland, lung, colon, liver, heart 
and spleen) were isolated, fixed during 2 hours in PBS/4%PFA and cryopreserved in PBS/20% sucrose 
overnight, both at 4°C. Pancreas were embedded, snap frozen in optimal cutting temperature (OCT) 






Immunofluorescence and TUNEL assay 
Pre-fixed tumors were cut with the cryotome in 7µm sections and air dried overnight. They were 
permealized with 0.1% Triton X-100 in PBS for 5min then blocked with a 5% BSA in PBS solution for 
one hour. Primary antibody were diluted in 1% BSA, 0.3% Triton X-100 in PBS. The following primary 
antibodies were used : rat anti-CD31 (BD, 550274, 1:40), rabbit  anti-cleaved  Caspase-3  (Cell  
Signaling, 9664,  1:50) and rabbit  anti-phospho Histone  H3  (Millipore,  06-570,  1:200). After over 
night incubation at 4°C, the samples were stained with species corresponding 2nd antibodies with either 
Alexa Fluor 488 or 568 (Molecular Probes, 1:250) for one hour at room temperature and nuclei were 
stained with DAPI (Sigma). 
Double strand  DNA  breaks  associated  with  apoptotic  and  non-apoptotic  cell  death were visualized 
using a fluorescent TUNEL assay (In Situ Cell Death Detection Kit, Fluorescin; Roche) according to 
the manufacturer`s recommendations, using Proteinase K pretreatment. Slides were then mounted with 
Dako Mounting Medium (DAKO) and stored at 4° until imaging. Fluorescence images were acquired 
with a microscope Olympus BX63. Images analysis and quantification was performed using Fiji 
distribution of ImageJ. 
 
Phosphoprotein analysis 
The PathScan® Akt Signaling Antibody Array Kit (Fluorescent Readout, #9700, Cell Signaling 
Technology, USA), Protease Inhibitor Cocktail 100x and the Pierce™ BCA Protein Assay Kit (Thermo 
Fischer Scientific, USA) were used for the biodistribution studies. 
For lysate preparation, the centrifuge was pre-cooled at +4°C and the aluminum blocks were put on ice. 
The lysis buffer (LB) was prepared by adding the Proteinase Inhibitor Cocktail, diluted 1:100 and used 
within 1 hour. 150µl of LB were needed for 1 tumor before physical crushing in a pre-cooled glass 
mortar. BCA assay was used to determine the total protein quantity.  
To perform the assay, PathScan® Akt Signaling Antibody Array Kit protocol was followed according 
to the manufacturer's instructions. 
The image was captured and analyzed by LiCOR Image Studio (Ver4.0 or later), analyzed with a grid 
array composed of 8x2 arrays, each consisting of 6 rows and 6 columns. The size of each case is 1005 
pixels and the background was adjusted. 
For the survival studies, we use a MSD Akt Signaling Panel II Base Kit (K15177A) and 4-EBP1 kit 
(K151OLD, MesoScale Discovery, USA). The protocol was followed according to the manufacturer's 
instructions. After lysate preparation like for the Pathscan protocol, the plate was read in a Sector 







Data were analyzed and graphs were generated with using IBM SPSS Statistics Ver. 22 or GraphPad 







High dose Everolimus pre-treatment reduces 177Lu-DOTA-exendin-4 tumor uptake 
Treatment for 3 days (Figure VIII-1A), 7 days (Figure VIII-1B) and 10 days (Figure VIII-1C) all show 
a significant decrease in 177Lu-DOTA-exendin-4 uptake at the higher dosis of 10 mg/kg bodyweight. 
The sub-therapeutic dose of 1mg/kg shows no reduction at all and 5mg/kg uptake is decreased 
significantly only after 7 days (p=0.01, Kruskal-Wallis). The pancreas (suppl. Figure VIII-1A), both 
kidneys (suppl. Figure VIII-1B) and all the other resected organs show no significant uptake (data not 
shown). Moreover, the receptor density is not affected after 10 days of Everolimus treatment at the 
highest dose (Figure VIII-1D). The inhibition of  mTOR  on its serine 2448 phosphorylation site 
(Ser2448) was confirmed by phophoprotein analysis for the 10mg/kg bodyweight compared to the 
control group and the 1 mg/kg bodyweight group (Figure VIII-1E). 
 
PRRT alone is sufficient to promote tumor shrinkage but acts synergistically with Everolimus 
The mean tumor weight is significantly reduced with PRRT as a single therapy and synergistically in 
combination with continuous Everolimus (Figure VIII-2A) but not if Everolimus is pulsed, i.e given 
every 3 days. Everolimus monotherapy does not significantly reduce tumor weight. Moreover, the 
average tumor number is statistically reduced in every treatment groups compared to control (figure 
VIII-2B) but the combined treatment acts synergistically in reducing average tumor number.  
Macroscopically we could observe a decrease of the average size and the color with less red-ish tumors 
(Supplementary Figure VIII-2). 177Lu-DOTA-exendin-4 SPECT/CT at day 0 and 30 days after 
beginning of combination treatment shows good tumor response to combined treatment (Figure VIII-
2C). 
 
Everolimus alone and in combination inhibits mTOR pathway and microvessel formation 
The microvasculature of the tumor was decreased by each treatment and each dose of Everolimus. The 
most significant decrease was reached by Everolimus continuously given at 5 mg/kg bodyweight (Figure 
VIII-3A) and represented microscopically by the Figure VIII-3B. In addition, the phosphor riboprotein 
S6, an essential downstream element of the mTOR pathway, was decreased in all the groups that 
received Everolimus in a daily manner (E cont, Figure VIII-3C). It is significantly higher when given 
every 3 days (E pulse). Other targets more downstream like Akt (Suppl. Figure VIII-3A), S6K (Suppl. 
Figure VIII-3B) and  4E-BP1 (Suppl. Figure VIII-3C) are not significantly inhibited. Only for 4E-BP1 
did intermittent Everolimus induce an up-regulation compared to control. 
 
Combined treatment tends to reduce proliferation and enhance apoptosis 
A TUNEL assay shows no significant differences between the control and the treated groups (Figure 





pattern. The proliferation is reduced for all the groups treated with 177Lu-Exendin-4, alone or in 
combination (Figure VIII-4B). They are significantly increased when the mice are treated with 
Everolimus alone and even more with Everolimus given intermittently. 
 
Combined treatment doesn’t significantly improve survival over Everolimus as single treatment 
The group treated with PRRT or  Everolimus every 3 days show no improvement over the control mice 
(Figure VIII-5). Combination of PRRT and Everolimus alone at 5 mg/kg bodyweight doesn’t improve 
survival compared to Everolimus given daily. In addition, to our knowledge, the 151 days of survival 







Objective response after 20 days of daily oral Everolimus administration as well as long term survival 
show a significant effect of Everolimus (5mg / kg bodyweight daily) compared to untreated control. At 
first glance these results seem to be contradictory to the study by Pool et al. that suspected promotion of 
metastases by Everolimus in a neuroendocrine tumor model (Pool et al. 2013; Bison et al. 2014). Using 
a protocol of Everolimus dosage similar to that of Pool et al. with intermittent administration of 
Everolimus in the Rip1Tag2 mice, the stable anti-tumor effect of (daily) Everolimus was lost or gave 
some sign of possible resistance. In fact the S6 and S6K phosphorylation was increased, as well as the 
proliferation marker pH3. We hypothesize that low or inconsistent levels of Everolimus may activate 
feed-back loop regulations that could lead to upregulation of mTOR pathway. This matches to results 
of the Rotterdam group that noticed promotion of metastases in a model of implanted tumors. 
 
Furthermore, our data suggest a dose dependent effect of Everolimus. While 1 mg/kg body weight/day 
did show only minor effect compared to 5 mg/kg bodyweight/day, 10 mg/kg bodyweight/day 
dramatically reduced tumor load after 20 days. The dose dependency of Everolimus in the treatment of 
Rip1Tag2 mice is in concordance to other previous studies in different animal models (Yao et al. 2011). 
With increased treatment length and increased dose of Everolimus we observed a reduced tumor uptake 
of 177Lu-Exendin-4. Since the receptor density is not changed, we interpret the biodistribution results as 
expression of treatment effect. 
 
As mentioned above, Everolimus daily at 5 mg / kg body weight significantly reduced tumor size and 
prolonged survival compared to control in Rip1Tag2 mice. PRRT with Lu-177-Exendin-4 showed 
tendency of tumor size reduction. Nevertheless, Everolimus significantly outperformed PRRT with Lu-
177-Exendin-4 (p<0.000). Combining both treatments resulted in a statistically significant objective 
response by tumor volume reduction of xxx and prolonged survival of 73 +/- 17.1 days. Interestingly, 
tumor volume reduction by combined treatment was significantly reduced compared to mono-therapy 
with daily Everolimus (p=0.001), survival of the combination treatment group was not prolonged when 
compared to mono Everolimus therapy. Rip1Tag2 is continuously creating new tumors under the 
impulse of the rat insulin promotor. Thus this animal model may not be the best to assess this question. 
 
One major drawback of our study is the lack of toxicity analysis. In our opinion, analyses of renal 
toxicity or bone marrow toxicity in Rip1Tag2 mice is unreliable and of limited value for clinical 
translation of our results. Since untreated Rip1Tag2 mice have a short life expectancy and kidney 
toxicity of PRRT occurs later in the course of treatment, any analyses of xxx would lack a sufficient 
control group. Second, Rip1Tag2 mice request PRRT with GLP-1 receptor analogue Exendin-4. 





or DOTATATE do. Results of kidneys toxicity analyses in Rip1Tag2 mice after exposure to Exendin-4 
aren’t comparable to DOTATOC-treatment in humans. 
 
Everolimus when administered properly has a very stable and high anti-tumor potential in the NET 
model of RIP1Tag2 mice. We hypothesize that as soon as the amount of Everolimus is reduced beyond 
a critical level, a significant number of individuals do not benefit or are even exposed to a risk of mTOR 
upregulation. Combing PRRT and mTOR inhibition additive treatment effect is preferable. In the mouse 
model, we demonstrated additive effects on tumor volume compared to single treatments of mTOR 
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Figure VIII-1 : Reduced uptake of radionuclide but same receptor density upon Everolimus pre-
treatment. 
 A, B and C, Mean tumor uptake +/- 95% confidence interval for 3, 7 and resp. 10 day of pre-treatmin 
with Everolimus. From left to right: control, 1 mg/kg body weight, 5 mg/kg body weight and 10 mg/kg 
body weight. n= 5-6 mice per group; *, P<0.05. D, Receptor density after  assay in dpm/mg tissue. 
Statistical analysis by Kruskal-Wallis test. N.S. means not significant. E, Relative Fluorescence Unit of 








Figure VIII-2 : Combination of Lu-177-Exendin4 and Everolimus dramatically reduces tumor 
formation. 
A, Mean tumor weight +/- 95% confidence interval for control (ctrl, n=9), Lu-177-Exendin4 (PRRT, 
n=9), Everolimus continuous (E cont, n=9), combination (Comb, n=10) and Everolimus pulse (E pulse, 
n=12) groups. Statistical analysis by Kruskal-Wallis test. B, Number of tumors per pancreas for control, 
Everolimus continuous, PRRT and combination treatment. Statistics are shown directly on the graph. 
C, PET-CT cross-sectional scans of a combination group mice. Left is baseline, right is after 30 days of 








Figure VIII-3 : Reduced microvessel density and decreased mTOR pathway activation upon treatment. 
A, Median percentage of the CD31+ area per view field for mice after 10 days of therapy. Statistical 
analysis by Mann–Whitney U test. **, P < 0.01. Right upper picture: immunofluorescence of CD31 in 
red and DAPI in blue for control mice and for combination mice in lower picture. B, Median 
phosphorylation of the downstream kinase phospho-S6 after 20 days of therapy. Statistical analysis by 








Figure VIII-4 : Apoptosis and proliferation.   
A, Median percentage of the TUNEL+ cells per view field for mice after 20 days of therapy. Statistical 
analysis by Mann–Whitney U test. Left picture: immunofluorescence of TUNEL in green and DAPI in 
blue for control mice and for combination mice in left picture. Scale bar = xx µm. B, Median percentage 
of the phospho-Histone3+ cells per view field for mice after 20 days of therapy. Statistical analysis by 
Mann–Whitney U test. Left picture: immunofluorescence of pH3 in green and DAPI in blue for control 








Figure VIII-5 : Increased survival in treated mice.  








Suppl. Figure VIII-1   
Pancreas and kidney uptake. A, Mean tumor uptake for the normal pancreas +/- 95% confidence interval 
for 3, 7 and resp. 10 day of pre-treatmin with 1, 5 and 10 mg/kg bodyweight Everolimus. B, Mean tumor 
uptake for the left kidney (left bar on each pair) and right kidney (right bar on each pair) +/- 95% 









Suppl. Figure VIII-2  
Number of tumors is decreased and the color of the tumors altered under combined treatment. 
Macroscopic comparison of the size and color of all the tumors isolated from one whole pancreas. Left 








Suppl. Figure VIII-3 
Other key target downstream of the mTOR pathway. Median phosphorylation of the downstream AKT 
(A), S6K (B) and p-4EBP1 (C) after 20 days of therapy. Statistical analysis by Mann–Whitney U test. 





IX. First in Human, Phase I, Dose Escalation Pharmacokinetic 
and Pharmacodynamic Study of the Oral Dual PI3K and 
mTOR Inhibitor PQR309 in Patients with Advanced Solid 
Tumors. 
 










PQR309 is an orally bioavailable, balanced pan–phosphatidylinositol-3-kinase (PI3K), mammalian 
target of rapamycin (mTOR) C1 and mTORC2 inhibitor. 
 
Patients and methods 
This is an accelerated titration, 3 + 3 dose-escalation, open-label phase I trial of continuous once-daily 
(OD) PQR309 administration to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics in 
patients with advanced solid tumours. Primary objectives were to determine the maximum tolerated 
dose (MTD) and recommended phase 2 dose (RP2D). 
 
Results 
Twenty-eight patients were included in six dosing cohorts and treated at a daily PQR309 dose ranging 
from 10 to 150 mg. Common adverse events (AEs; ≥30% patients) included fatigue, hyperglycaemia, 
nausea, diarrhoea, constipation, rash, anorexia and vomiting. Grade (G) 3 or 4 drug-related AEs were 
seen in 13 (46%) and three (11%) patients, respectively. Dose-limiting toxicity (DLT) was observed in 
two patients at 100 mg OD (>14-d interruption in PQR309 due to G3 rash, G2 hyperbilirubinaemia, G4 
suicide attempt; dose reduction due to G3 fatigue, G2 diarrhoea, G4 transaminitis) and one patient at 80 
mg (G3 hyperglycaemia >7 d). PK shows fast absorption (Tmax 1–2 h) and dose proportionality for 
Cmax and area under the curve. A partial response in a patient with metastatic thymus cancer, 24% 
disease volume reduction in a patient with sinonasal cancer and stable disease for more than 16 weeks 
in a patient with clear cell Bartholin's gland cancer were observed. 
 
Conclusion 
The MTD and RP2D of PQR309 is 80 mg of orally OD. PK is dose-proportional. PD shows PI3K 
pathway phosphoprotein downregulation in paired tumour biopsies. Clinical activity was observed in 
patients with and without PI3K pathway dysregulation. 
 
Clinical trial registration 






• The maximum tolerated dose and recommended phase 2 dose of PQR309 is 80 mg orally OD. 
• Pharmacodynamics shows phosphatidylinositol-3-kinase (PI3K)–mammalian target of 
rapamycin (mTOR)–S6 pathway inhibition in paired tumour biopsies. 
• Pathway inhibition is more pronounced in patients with tumour shrinkage. 
• Activity was observed in patients with and without PI3K pathway dysregulation. 
• Tumour-associated immune infiltrates were not affected by PI3K/mTOR inhibition. 
 
Introduction 
The phosphatidylinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) signaling 
cascade serves physiological and pathophysiological cell functions and is of major importance in cancer 
and inflammatory disease. As a key downstream effector of receptor tyrosine kinases (RTKs) and G 
protein coupled receptors (GPCRs), PI3K activation initiates a signal transduction pathway that 
stimulates glucose metabolism, cell proliferation, growth, and survival (Yuan & Cantley 2008; Courtney 
et al. 2010; Banham-Hall 2012; So & Fruman 2012; So et al. 2013; Engelman 2009; Brana & Siu 2012; 
Rodon et al. 2013; Liu et al. 2009). One of the principal downstream effectors of PI3K is mTOR. mTOR 
also integrates growth signals that are independent of PI3K activation (Engelman 2009). Dysregulation 
of the PI3K/mTOR pathway is associated with many cancers. Inappropriate activation of the pathway 
may occur through a variety of mechanisms including (i) activating mutations, amplifications, or 
overexpression of the p110α subunit (PI3KCA); (ii) constitutively active mutants or overexpression of 
upstream receptor tyrosine kinases (e.g. epidermal growth factor receptor, insulin-like growth factor 
receptor, Erb-B2, Erb-B3); (iii) constitutive recruitment and activation by Ras oncogene mutants; (iv) 
loss or inactivating mutations of Phosphatase and tensin homolog (PTEN), an endogenous negative 
regulator of the pathway; or (v) overexpression and activating mutations of downstream kinases (e.g., 
Akt) (Courtney et al. 2010; Engelman 2009). In addition, dysregulation of the PI3K/mTOR pathway has 
been implicated in chemotherapy resistance (Courtney et al. 2010; Engelman 2009; Liu et al. 2009; 
Samuels et al. 2004; Koti et al. 2013; Saura et al. 2014).  
 
To date, PI3K and PI3K/mTOR inhibitors have demonstrated clinical efficacy in patients with cancers 
harboring PIK3CA (Baselga J, Im S-A, Iwata H 2015) or PTEN aberrations and also in some patients 
without detected mutations in these pathways. Idelalisib, a selective inhibitor of  PI3Kδ is licensed for 
use in chronic lymphocytic leukaemia and follicular lymphoma (Janku et al. 2014; EMA 2016; FDA 
2016). Similar clinical outcomes have been reported for duvelisib (a PI3K γ/δ inhibitor) and TGR-1202 
(another PI3Kδ-selective inhibitor) (Patel et al., 2015 ; O’Connor et al., 2015). Everolimus, a selective 
inhibitor of mTORC1, is licensed for use in advanced breast cancer, neuroendocrine tumors, and renal 





been shown to occur either due to novel mutations within the targeted kinase, or to other compensatory 
mechanisms (Van Der Kuip et al. 2005; Barouch-Bentov & Sauer 2011; Daub et al. 2004). In particular, 
it has been shown that idelalisib resistance is due to increased expression of PI3Kα (Meadows et al. 
2015). Alternatively, inhibiting all PI3K isoforms results in upregulation of the mTOR pathway or 
inactivation of PTEN, accompanied by resistance to these agents (Elkabets et al. 2013). Persistent 
mTOR activation has been detected in patients with PIK3CA-inhibitor resistant tumors. Thus, targeting 
two nodal points within a pathway may reduce the probability of resistance or increase the latency period 
prior to the development of resistance (Elkabets et al. 2013). Dual inhibition of PI3K and mTOR is 
therefore a promising strategy for anticancer therapy.  
 
PQR309 (Piqur Therapeutics AG, Basel, Switzerland) is an oral pan-class I PI3K inhibitor that 
selectively targets all four isoforms of class I PI3K (α, β, γ, δ), with a balanced activity against mTOR. 
It is equipotent against p110αH1047R/E542K/E545K somatic mutations often observed in human cancers 
(Beaufils et al. 2017). PQR309 demonstrates anti-proliferative activity in a variety of cell lines with and 
without inappropriate PI3K pathway activation (Cmiljanovic et al. 2015; Tarantelli et al. 2018; 
Tarantelli C, Gaudio E, Kwee I, Rinaldi A, Bernasconi E, Cascione L 2015; Bohnacker et al. 2017). 
 
The primary objectives of this first-in-human, phase 1, dose-escalation study were to assess the safety 
and tolerability and determine the MTD and RP2D of oral PQR309 with once-daily continuous dosing 
in patients with advanced solid tumors. Secondary objectives included characterization of the 







Patient & Methods 
Ethics 
This study was conducted in accordance with the Declaration of Helsinki and the guidelines of Good 
Clinical Practice (GCP) issued by the International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH), the European Union (EU), and 
the Swiss Confederation. The study protocol was approved by ethics committees and regulatory 
authorities for all participating institutions. All participants provided written informed consent prior to 
participation in the study. 
 
Study design 
This was a multicenter, international, open-label first-in-human trial. Based on the No-Observed-
Adverse-Effect-Level (NOAEL) in dogs of 4mg/kg, the starting dose in humans was 10mg. An 
accelerated modified “3+3” dose-escalation design was used. Dose level 1 and 2 enrolled a single patient 
(pre-determined), with evaluation of a single cycle with no toxicity ≥ G2 prior to enrolment at the next 
dose level. If a drug-related toxicity ≥ grade 2 occurred, two additional patients were to be enrolled at 
the same dose level and then the trial would continue as a classical 3+3. From dose level 3 and thereafter, 
the classical 3+3 design was used. Doses were increased by 100% between dose-levels until dose level 
4. After dose level 4 or the first toxicity ≥ grade 2, subsequent dose levels could increase between 30-
100%, according to the type and grade of toxicity after discussion with the independent data safety 
monitoring board (IDSMB). In dose levels 2 to 4, the administered dose was adjusted according to 
weight (75% dose if < 60kg, 125% dose if > 80kg). Eligible patients received once daily oral PQR309 
capsules continuously on a 21 day cycle until progression, unacceptable toxicity, investigator 
judgement, or withdrawal of consent. 
 
Patients 
The study enrolled adult patients (age ≥ 18 years) with a histological or cytologically confirmed 
diagnosis of advanced solid tumor and evidence of tumor progression with measurable or evaluable 
disease for which no therapy of proven efficacy was available. The inclusion criteria were updated after 
recruitment of the four initial cohorts to require tumors accessible to biopsy (initially optional). Patients 
were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1, and 
adequate hematological [absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, 
hemoglobin ≥ 90 g/L], liver [total bilirubin ≤ 1.5 times the upper limit of normal (ULN), alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 ULN or ALT/AST ≤ 5 times ULN 





per day of prednisolone or equivalent] were prohibited. Patients were required to be able to swallow and 
retain oral medication and be willing and able to comply with trial procedures.  
Exclusion criteria included medical conditions that could significantly interfere with study drug 
metabolism, pre-existing diabetes, a fasting glucose > 7 mmol/L or HbA1c > 6.4% (6% in initial 
cohorts), patients with symptomatic or progressing central nervous system metastases, persisting 
toxicity ≥ grade 2 secondary to prior anticancer therapy, ischemic heart disease, heart failure (New York 
Heart Association Class 3 or 4), uncontrolled hypertension, known HIV, serious infection or medical 
condition which would jeopardize compliance with the protocol. Patients who were pregnant, breast-
feeding, or unwilling to use appropriate contraceptive measures were excluded.  
 
Dose limiting toxicity, maximum tolerated dose, and management of toxicity 
DLTs were defined as any of the following: grade 4 neutropenia for > 7 days, febrile neutropenia, grade 
4 thrombocytopenia, grade 4 non-hematological toxicity (e.g. hyperglycemia > 27.8 mmol/L) or grade 
3 lasting > 7 days (unless controlled with supportive care), treatment delay > 14 days due to unresolved 
toxicity, or non-hematological toxicity ≥ grade 2 deemed dose limiting by the IDSMB. DLTs were based 
on adverse events observed during the first cycle (21 days). The MTD was defined as the highest dose 
level at which ≤ 1 out of 6 patients experience a DLT.  
Management algorithms for the treatment expected toxicities of hyperglycemia, maculopapular rash, 
acneiform rash, pruritus, and dry skin were defined in the protocol.  
 
Safety & efficacy assessments 
Monitoring for adverse events, concomitant medications, vital signs, physical examination, weight, 
performance status, hematology, blood chemistry including glucose, HbA1c, hemostasis, and urinalysis 
were performed at baseline, weekly in the first two cycles, and once a cycle thereafter. In addition, 
screening and baseline assessment included medical history, tumor history, and a pregnancy test. ECG 
was checked at baseline and every two cycles. Adverse events were graded using the National Cancer 
Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 4.03. Serious adverse 
events were defined as any event that was fatal, life-threatening, required inpatient hospitalization > 24 
hours, prolonged hospitalization, was disabling, any new secondary malignancy, a congenital anomaly, 
or any medically significant condition that occurred between registration and up to 28 days after the last 
dose of PQR309.  
Efficacy parameters were defined using the Response Evaluation Criteria in Solid Tumors (RECIST 
version 1.1). Tumor assessment by CT or MRI of the tumor area, thorax, and abdomen occurred at 





imaging had been performed in the previous 14 days. Tumor markers were assessed at baseline and 
every 3 weeks. 
 
Pharmacokinetics 
Blood samples were collected for PK analysis immediately prior to the first dose; 1, 2, 6, and 24 hours 
following the first dose of PQR309, 24 hours after the last dose of cycle 1 and prior to the first dose of 
cycle 2. PQR309 concentrations were determined by high-performance liquid chromatography tandem 
mass spectrometry (assay range: 1.00-1000ng/ml).   
 
Pharmacodynamics 
Where feasible, patients underwent tumor biopsy (initially optional, compulsory following protocol 
amendment June 2014) prior to treatment initiation and at the end of cycle 1. Samples underwent next 
generation DNA sequencing (Ion AmpliSeq™ Cancer Hotspot Panel v2 panel, analysis of expression 
of 88 PI3K- and mTOR related mRNAs (RT2 Profiler PCR Array) (Suppl. Figure 1), analysis of 
phosphorylation of 16 PI3K/mTOR associated phosphorylation sites (PathScan® Akt Signaling 
Antibody Array Kit, Pierce™ BCA Protein Assay Kit), and stained for CD3, CD4, CD8, and FoxP3 
positive T cells immune infiltrate. If samples were insufficient for all intended translational analyses, 
analysis was prioritized as follows: assessment of phosphoproteins, next generation sequencing, analysis 
of immune infiltrates and RNA array. 
Blood samples for fasting glucose and insulin were collected immediately prior to the first dose of 
PQR309, 1 and 24 hours following the first dose, and at day 21 of cycle 1 following a protocol 
amendment (June 2014). 
 
Biopsy handling 
Upon reception at the University Hospital Basel, the two biopsies were taken out of the cryotube, and 
placed on a pre-cooled aluminum block on dry ice. At the time when the isopentan was evaporated, the 
biopsies were measured with a caliper, photographed, and the macroscopic properties were assessed and 
documented. One of the two biopsy cores was dedicated for RNA analysis, and was embedded in a 
horizontal position. The other biopsy, usually the thicker one, was dedicated to phospho-protein 
applications and was embedded vertically. The sample was then placed in a plastic cryomold on dry ice 
and a drop of slightly pre-cooled optimal cutting temperature (OCT) embedding medium was added. 
The frozen biopsy was taken with a pre-cooled forceps, put on the bottom of the cryomold and the mold 
was filled with OCT. After 10 minutes, the cryomold was put in a labeled, sealed minigrip and stored in 






Freshly frozen biopsies embedded in OCT and stored at -80°C were cutted in a cryotome in serial 
sections. One serial section cycle was composed of three 7µm thick sections followed by ten 40µm thick 
sections stored in pre-cooled Eppendorf on dry ice. The excess of OCT was carefully removed with a 
pre-cooled scalpel before being transferred in the Eppendorf. The first 3 sections of each cycle were 
then stained for H&E and evaluated by a pathologist. The sections were then evaluated for the tumor 
content in percentage of the positive cross-sectional area and the tissue quality was designated with a 
scoring system from 1 (poor quality) to 3 (high quality) as assessed by the pathologist. The selection of 
slides for further use was based on the evaluation of the pathologist: the cut-off for the tumor content 
was 30%, and 2 for the scoring system. In case of biopsies with a smaller cross-sectional area than 
average, two cycles of the same tumor biopsy were lysed in the same Eppendorf.  
 
Phosphoprotein analysis 
The PathScan® Akt Signaling Antibody Array Kit (Fluorescent Readout, #9700, Cell Signaling 
Technology, Denvers MA, USA) and Protease Inhibitor Cocktail 100x were purchased at BioConcept 
AG (Allschwil, Switzerland), and the Pierce™ BCA Protein Assay Kit (Thermo Fischer Scientific, 
USA) were purchased at LuBio Science GmbH (Switzerland). The Laboratory of Tumor Immunology 
and Biology and the Department of Biomedicine of the University of Basel provide the laboratory 
equipment.  
For lysate preparation, the centrifuge was pre-cooled at +4°C and the aluminum blocks were put on ice. 
The lysis buffer (LB) was prepared by adding the Proteinase Inhibitor Cocktail, diluted 1:100 and used 
within 1 hour. 110µl of LB are needed for 1 serial section cycle, 200µl for 2 cycles pooled together. The 
Eppendorf containing the biopsy slice was taken out from the -80°C freezer to let them equilibrate in an 
aluminum block for 2-3 minutes. Then, 110µl or 200µl, respectively, of LB was added, pipetted up and 
down 10-15 times without creating bubbles and incubated for 5 min. The Eppendorf’s were centrifuged 
for 10 min at minimally 13'000 rpm in a pre-cooled centrifuge (+4°C). The supernatant was then 
transferred to a new pre-cooled and labeled Eppendorf. 
For determination of the protein concentration, the dilutions of the standard albumin and the assay were 
prepared accordingly to manufacturer's instructions. The plate was read at 562nm in an ELISA reader. 
The values were copied in the BCA_excel layout and the linear regression curve equation was calculated 
to determine the amount of total proteins. 
To perform the assay, PathScan® Akt Signaling Antibody Array Kit protocol was followed according 
to the manufacturer's instructions. The protein lysate was incubated 2 hours at room temperature and 
20µg of total protein were assessed in 75µl, which means 0.26mg/ml (recommended range [0.2-
1.0mg/ml]). The first four blocks of each plate were used for the standard lysate. It was made of MCF7 





concentration corresponds to 10 times the sample concentration, the second 1 time, the third 0.1 time 
and the fourth 0.01 time. 
The image was captured and analyzed by LiCOR Image Studio (Ver4.0 or later). The scanning 
properties were set to high quality, 21µm/px, 0.0mm interval and intensity 2.0. After rotating from the 
right to the left, the image was analyzed with a grid array composed of 8x2 arrays, each consisting of 6 
rows and 6 columns. The size of each case is 1005 pixels and the background was adjusted by selecting 
the spot at the right bottom. 
All data were exported in an excel file and then analyzed with GraphPad Prism (Ver6.0f or later). The 
Wilcoxon signed-rank test, a nonparametric test that compares the median of a column of numbers 
against a hypothetical median (median=100) was chosen to test the significance. The comparison 
between samples from patients with growing or shrinking tumors was analyzed through the Mann-
Whitney test, a non-parametric test that compares the distributions of two independent groups. 
 
RNA analysis  
Zymo Research Direct-zol RNA MiniPrep and Tri-zol Extraction Buffer (#T9424, Sigma Aldrich) were 
purchased at Lucerna Chem AG (Switzerland). PI3K-AKT specific RT2 PreAMP cDNA Synthesis 
(#PBH-058Z, Sabioscience, Qiagen) and RT2 Profiler PCR Array (#PAHS-058Z, Sabioscience, Qiagen) 
were purchased at Qiagen AG (Switzerland) (Suppl. Figure IX-1). The Laboratory of Tumor 
Immunology and Biology and the Department of Biomedicine of the University of Basel provided the 
laboratory equipment and the Applied Biosystems ViiA7 PCR cycler. 
For RNA extraction, the Eppendorf containing the biopsy slice was taken out from the -80°C freezer to 
let them equilibrate in an aluminum block for 2-3 minutes in the chemical hood, sprayed with RNAlater. 
500µl of Trizol were added to each sample, and the sample was vortexed at least 3 times. 500µl of 
absolute ethanol was added and vortexed again 3 times. RNA was extracted with the Direct-zol RNA 
MiniPrep kit according to the manufacturer's instructions. The optional genomic DNA digestion step 
was added. The elution buffer was 25µl and was run through the column two times with centrifugation. 
The eluate was put directly on ice. RNA purity and concentration were assessed by Nanodrop. The 
sample was released only if it matched the 4 following criteria: (i) A260:A230  ratio > 1.7, (ii) A260:A280  
ratio  = [1.8; 2.0], (iii) Concentration by A260 > 6ng/µl, and (iv) biopsy A and biopsy B from the same 
patient were available. 
For specific pre-amplification, between 60 and 100ng of RNA (recommended range [10-100ng] in 8µl 
were preamplified by PI3K-AKT RT2 PreAMP cDNA Synthesis according to the manufacturer's 
instructions. 
For quantitative PCR, the PI3K-AKT specific RT2 Profiler PCR Array protocol for 384-well plate (type 






Libraries preparation using the Ion AmpliSeq™ Cancer Hotspot Panel v2 panel (Thermo Fisher 
Scientific) were performed following the manufacturer’s instructions and as previously described 
(Dacheva et al. 2015; Simen et al. 2015). The Ion AmpliSeq™ Cancer Hotspot Panel v2 panel was 
designed to allow amplification-based capture and sequencing of coding regions of 50 cancer-related 
genes (http://tools.thermofisher.com/content/sfs/brochures/Ion-AmpliSeq-CancerHotspot-Panel 
Flyer.pdf). This panel includes 207 primer pairs and requires a minimum initial amount of 10 ng of DNA 
as input. After DNA extraction and quantification, multiplex PCR for targets enrichment was performed 
using genomic DNA mixed with primer pools and the Ion AmpliSeq™ HiFi master mix (Ion 
AmpliSeq™ Library Kit 2.0, Thermo Fisher Scientific) for 2 min at 99°C, followed by 22 cycles of 
99°C for 15 sec and 60°C for 4 min and holding at 10°C. The obtained PCR products were sub 
sequentially treated with 2 μL of FuPa reagent (Ion AmpliSeq™ Library Kit 2.0, Thermo Fisher 
Scientific) to partially digest the primer sequences and then phosphorylated at 50°C for 10 min, followed 
by 55°C for 10 min, and finally at 60°C for 20 min. The generated amplicons were ligated to Ion beads 
adapters (Ion AmpliSeq™ Library Kit 2.0, Thermo Fisher Scientific) and sample-specific barcodes from 
the Ion Xpress™ Barcode Adapters kit (Thermo Fisher Scientific) for 30 min at 22°C and then at 72°C 
for 20 min. Afterwards, the generated barcoded libraries were purified using Agencourt® AMPure® XP 
reagents (Beckman Coulter). The library concentration was determined using an Ion Univesal Library 
Quantitation Kit (Thermo Fisher Scientific) and the amplicons size controlled with the Bioanalyzer 2100 
(Agilent). 30 pM for each library were loaded into the IonChef System using the IC Hi-Q sequencing 
Kit for fully automated emulsion polymerase chain reaction (PCR) and chip loading (6 samples were 
multiplexed on one 318v2 chip). Finally, loaded chips were sequenced using the Ion PGM Hi-Q 
Sequencing Kit using the IonPGM (500 flows). 
Raw data (BAM files) for each sample were processed for the alignment of sequencing reads with the 
human genome reference (hg19) using the Torrent Suite software v5.0 (Thermo Fisher Scientific). The 
alignment pipeline also included signaling processing, base calling, quality score assignment, adapter 
trimming, PCR duplicate removal and control of mapping quality. Local re-alignment, duplicate 
removal and quality base score recalibration were as well carried out using the Genome Analysis Toolkit 
(GATK) (McKenna et al. 2010). Coverage metrics for each amplicon (minimal acceptable coverage 
threshold was set at 300x) was obtained by running the Coverage Analysis Plugin software v5.0.1 
(Thermo Fisher Scientific). Base calling was performed using the IonReporter v5.0 (Thermo Fisher 
Scientific). In additions, also MuTect (Cibulskis et al. 2013) and Varscan2 (Koboldt et al. 2012) 
algorithms were used to call somatic single nucleotide variants (SNVs) and Varscan2 (Koboldt et al. 
2012), Strelka (Saunders et al. 2012) and Scalpel (Narzisi et al. 2014) for insertions and deletions 
(indels). We have chosen these specific mutations caller strategy as it allows identifying somatic 





mutation). Finally, all candidate mutations were manually reviewed using the Integrative Genomics 
Viewer (Robinson et al. 2011; Thorvaldsdóttir et al. 2013).  
 
Staining for CD3, CD4, CD8 and FoxP3 positive cells in tumor biopsies 
Immunohistochemistry was performed on an automated immunostainer (Benchmark, Ventana/Roche). 
The primary antibody for CD3 was purchased from Ventana/Roche (ab790-4341, Tucson, Arizona). 
Antigen retrieval pre-treatment was achieved by mild cell conditioning with CC1 for 32 minutes. The 
antibody was incubated 12 minutes and detected applying OptiView and diaminobenzidine as 
chromogen. Finally, slides were counterstained with hematoxylin and bluing reagent (all from 
Ventana/Roche). 
The primary antibody for CD8 was purchased from Ventana/Roche (ab790-4460, Tucson, Arizona).  
Pretreatment with CC1 was for 24 minutes, the antibody incubation time 16 minutes.  
The primary antibody for was purchased from Ventana/Roche (ab790-4423, Tucson, Arizona). Pre-
treatment was for 16 minutes with CC1, the antibody incubation time 12 minutes.  
The primary antibody for FoxP3 was purchased from Abcam (ab22510, Cambridge, UK). Pre-treatment 




Patient demographics, adverse events, PK and efficacy data were presented using descriptive statistics. 
Patients evaluable for safety analysis were defined as all patients who received at least 1 dose of 
PQR309. The DLT evaluable population was defined as all patients who missed no more than 1/3 of 
doses during the first cycle including any patient who experienced a DLT during cycle 1 regardless of 
the number of doses received. Patients who did not complete 1 cycle of treatment for reasons other than 
study related toxicity were replaced.  
Analysis was performed using SAS version 9.2. GraphPad Prism 6 (GraphPad Prism Software Inc.) was 







Twenty-eight patients (20 female, 8 male) were treated between January 2014 and February 2015 at six 
centers (Switzerland, the United Kingdom and Spain) (Table IX-1). Patients were enrolled into six 
dosing cohorts (10mg n=1; 20mg n=1; 40mg n=4; 80mg n=9; 100mg n=7; 120mg n=6), with dose 
adjusted for body weight in the first four cohorts (Table IX-2). The median age of patients was 58 years 
(range 21-75). The most frequent primary tumor types were colorectal cancer (n=7) and ovarian cancer 
(n=6). The study population was heavily pre-treated: the median number of lines of prior treatment was 
4 (range 0-9; Table IX-1). Fourteen patients (50%) discontinued trial treatment due to progressive 
disease. Five patients discontinued due to adverse events (18%), six due to withdrawal of consent (21%; 
toxicity and intolerance of supportive therapies were given as reason), one due to death secondary to 
cancer, and one was withdrawn by the investigator. One patient left the trial after 21 cycles and continued 
PQR309 treatment within the framework of a compassionate use program. 
 
Adverse events  
Fatigue was the most common adverse event in this trial (Table IX-3). 26 of 28 patients (93%) 
experienced at least one episode of fatigue. Of those, 3 (11%) had fatigue grade 3-4.  
Hyperglycemia was observed in 25 (89%) patients, 7 (25%) had G3-4 hyperglycemia. Blood glucose 
levels, PQR309 dosage and anti-hyperglycemic therapy are presented graphically (Suppl. Figure 2). 
Hyperglycemia onset was 7-14 days after commencing PQR309.  The median time to normalization of 
blood glucose levels after stopping PQR309 was 7 days. Hyperglycaemia was managed with metformin, 
sulfonylureas, SGLT-2 inhibitors, and insulin.  Insulin was required in 5 of the 7 patients with G3-4 
hyperglycemia.  
Anorexia occurred in 15 patients (54%) and weight loss >5% in 13 (46%) participants. Weight loss was 
reversible after stopping PQR309.  
8 (29%) patients developed a maculopapular rash which was G3-4 severity in 5 patients. Corticosteroids 
were effective and induced rapid remission of the rash.  
Depression was observed in 6 (21%) patients.  In 1 patient (4%) a psychotic episode with suicide attempt 
was witnessed a few days after stopping the trial drug. No Grade 5 toxicities were observed.  
 
Dose-limiting toxicities 
Dose-escalation continued to 120mg once daily. No DLT was observed in the initial four dose-escalation 
cohorts up to 80mg daily (Table IX-2). Although no formal DLT was declared in the 120mg cohort, the 
investigators judged this dose to be above the maximum tolerated dose due to the frequency of Grade 3 





vomiting, diarrhea, broncho-pulmonary infection, hypoxia, ALT increase, AST increase, ALP increase, 
headache, and hypertension in 1 patient. Based on this assessment, an additional cohort was accrued at 
the 80mg flat dose level. No DLT occurred. As specified by the protocol an intermittent dose level of 
100mg daily was opened. In this cohort, a G3 rash and G4 suicide attempt in a patient with colorectal 
cancer was considered a DLT. A second DLT in the 100mg cohort occurred in a patient with ovarian 
cancer at the same dose level who experienced G3 fatigue, G3 diarrhea and G3 elevation of liver 
enzymes. Given 2 DLTs in the 100mg cohort, three additional patients were enrolled in the 80mg cohort, 
of whom one patient experienced a DLT (G3 hyperglycemia for more than 7 days). Given a single DLT 
in a cohort of nine patients, 80mg was declared the maximum tolerated dose and the recommended 
phase 2 dose (RP2D) for continuous daily dosing of PQR309. 
 
Response 
Twenty-four patients were evaluable for response by radiological assessment of target lesions using 
RECIST v1.1 (Table IX-2). A partial response was observed in one patient. Best response of stable 
disease or progressive disease was observed in nine and fourteen patients respectively. The median 
duration of treatment was 41.5 days (range 12-446). Two patients were on treatment for over 100 days; 
a patient with thymic carcinoma with a known RICTOR1 amplification with a partial response on 
imaging (ongoing on day 705 ); and a patient with Bartholin’s gland carcinoma with a SMARCB1 
mutation and stable disease (152 days).  
 
Pharmacokinetics 
Absorption was moderately fast to fast. The peak plasma concentration, Cmax, was generally reached 
between 1 to 2 hours after oral administration of PQR309, except for some patients at 50, 80 and 120 
mg PQR309 where Cmax was reached at 6 to 24 hours after oral administration of PQR309. The average 
peak concentration (Cmax) and exposure (AUClast) increased with increasing dose levels of PQR309 
in a roughly dose proportional manner; with a minimum of 49.9 ng/mL and 273 h*ng/mL (15 mg) and 
a maximum of 998 ng/mL (150 mg) and 12600 h*ng/mL (120 mg), for Cmax and AUC respectively. 
The variability per group in the PK parameters Cmax and AUC, evaluated by %CV, varied from 13 to 
80%. After repeated administration of PQR309 most patients showed higher plasma values after 21 days 
of treatment of PQR309 as compared to the pre-dose levels on Day 2 (=24-hour post first dose on Day 
1), independent of  dose level. Average accumulation ratios when comparing pre-dose Day 22 (Cycle 2 
Day 1) to pre-dose  Day 2 (=24 hours post first dose on Day 1, Cycle 1) varied from 1.0 to 9.7, and were 
not dose-related. T1/2 of PQR309 is estimated to be around 40 hours from the 0-24 hour profile carried 







17 patients had at least one tumor biopsy taken for pharmacodynamic analysis, although not all samples 
were sufficient for all planned translational assays. 
  
Sequencing of tumor samples revealed a variety of sequence variations and amplifications (Table IX-
2). Two patients had variations detected in their tumors that may have influenced the observed response 
to PQR309. A patient with thymic carcinoma treated at 100mg daily had an amplification of RICTOR, 
a component of mTORC2. This patient experienced a partial response (-42%) which lasted for more 
than 700 days. A patient with sinunasal cancer, also at 100mg daily, had an activating PIK3CA mutation; 
a minor response occurred in this patient.  
 
The analysis of 88 PI3K-related mRNAs (Suppl. Figure IX-1) in PTB of 6 patients showed a non-
significant threefold upregulation of PDGFRA (Suppl. Figure IX-3). No consistent up- or 
downregulation of the remaining 87 mRNAs was detected. Thus, there is no indication of transcriptional 
feedback regulation after 21 days of therapy with PQR309. No association of the analysed mRNAs and 
response was observed.  
 
Samples from 13 patients were eligible for the analysis of phospho-proteins. Table 4 summarizes key 
characteristics of the 13 eligible paired biopsies. Changes in the level of phosphorylation are 
demonstrated in Figure IX-1 and supplementary Figure IX-4. Akt phosphorylation sites (Thr308 and 
Ser473), p-mTOR, p-S6-RiboProtein, p-AMPKa, p-PRAS40, p-GSK3b, p-Bad, p-RSK1, p-PTEN and 
p-Erk1/2 were significantly downregulated in comparison to baseline (p<0.05, Wilcoxon signed-rank 
test). p-4E-BP1, p-GSK3a  and p-PDK1 showed a trend to reduced phosphorylation, but this was not 
statistically significant. Patients with tumor reduction by radiological assessment had stronger p-Akt 
Thr308, p-mTOR Ser2481 and phospho-S6-RiboProtein Ser235/236 (figure IX-1, suppl. figure IX-4) 
suppression than those with tumor increase (p<0.05, Mann-Whitney test). Importantly, MAPK activity 
(Erk1/2 phosphorylation) was the same in patients with tumor shrinkage as compared to those with 
tumor growth. Due to the small sample size per dose level, the trial lacked power to show a dose-
dependent downreguation of PI3K-mTOR associated phospho-proteins.  
 
The results of the analysis of immune infiltrates in tumor biopsies are shown in Figure 2. No significant 







This first-in-human trial investigated the tolerability and RP2D of PQR309, an oral dual inhibitor of 
pan-PI3K and mTORC1/2. The main adverse events were fatigue, hyperglycemia, loss of appetite and 
rash. Six patients (21%) had depression, and amnesia was recorded in one patient (4%).  The profile of 
AEs was broadly similar to that of other pan-PI3K inhibitors such as Buparlisib (NVP-BKM120) or dual 
inhibitors such as NVP-BEZ235 (Di Leo et al. 2016). The MTD and RP2D of PQR309 was defined as 
80mg continuous once daily in advanced solid cancers. Clinical activity including a partial response was 
observed in patients with and without known PI3K pathway dysregulation. The pharmacokinetic profile 
suggests dose proportionality and a half-life of 40 hours. Based on the observed toxicity profile and the 
PK data, alternating dose schedules of PQR309 or 2 days on / 5 days off regimens should be evaluated.  
 
NGS of tumor tissue identified a range of mutations that reflect the known heterogeneity of advanced 
cancers. Although it is rational to hypothesize that tumors harbouring activating PI3K or mTOR 
mutations respond better to PI3K-mTOR inhibitors than tumors without, only the BELLE-2 trial has 
been able to assign a predictive value to such mutations (Baselga J, Im S-A, Iwata H, 2015). In the 
present trial, one patient with RICTOR amplification (Cheng et al. 2015) and one with an activating 
PI3K mutation (PIK3CA p.Glu545Lys) derived benefit from the trial medication. The overall predictive 
value of PI3K pathway mutations remains unconfirmed. The analysis of PI3K related mRNAs showed 
a threefold upregulation of PDGFRA during PQR309 therapy. However, the result did not cross the pre-
defined boundary for statistical significance and no predictive value could be assigned to mRNAs 
associated with PI3K signaling. Despite this, upregulation of PDGFRA may represent a mechanism of 
resistance and should be further evaluated in future trials with PQR309. 
 
Exposure to PQR309 significantly downregulates the signaling activity of several PI3K-mTOR 
associated phospho-proteins, indicating that PQR309 effectively inhibits the intended targets in patients. 
Consistent with previous preclinical data, PQR309 can also inhibit Erk1/2 signalling in patients. The 
sample size (1-6 patients per dose level) is too small to show dose-dependent downregulation of 
PI3K/Akt/mTOR signaling. However, a more pronounced downregulation of p-Akt Thr308, p-mTOR 
Ser2481 and p-S6-RiboProtein Ser235/236 was observed in those patients whose tumors reduced while 
on therapy. Whether this correlates with a higher baseline activation of PI3K/mTOR or is due to a 
stronger inhibitory effect of the drug in responding patients cannot be determined with any certainty 
from the experimental data. From the perspective of predicting response to PI3K/Akt/mTOR pathway 
inhibition, it seems that the concomitant downregulation of p-Akt Thr308 and mTORC1 activity in 
patients treated with PQR309 may be indicative of tumors that respond. On examination of all the 
phosphorylation data, phosphorylation sites closely associated with  activation of  p-Akt Thr308 and 





downregulated because S6K depends on p-Akt Thr308 activation. In contrast, S6K phosphorylation 
does not need p-Akt Ser4738. Furthermore, p-mTOR Ser2481, which is auto-phosphorylated by TSC1/2 
and then p-Akt Thr308, is also downregulated. In addition, there is evidence that TSC1/2 
phosphorylation can be triggered by isolated p-Akt Thr308 phosphorylation and p-mTOR S2481 is also 
reported to associate with mTORC2 (Copp et al. 2009).   
 
The  exceptions in this dataset are GSK3a and b, which are thought to rely on p-Akt Thr308. However, 
they are also reported to be targeted by PKC, which may account for the observed discordance. The 
decrease of PDK1 is not significant.  
 
PI3K signalling is involved in the activation of T-cells. There was no evidence that therapy with a dual 
PI3K-mTOR inhibitor induced immunosuppression in this trial. The analysis of immune infiltrates 
showed no downregulation of CD8-positive cytotoxic T cells or upregulation of regulatory T cells.  
This trial supports further clinical investigation of PQR309 which continues in phase I andII trials 
including solid tumors with activating PI3K mutations (alternative dose scheduling and more intensive 
PK testing (NCT02850744), lymphoma (NCT02249429), glioblastoma multiforme (NCT02850744), 
and CNS lymphoma (NCT02669511). The cytostatic nature of PI3K/mTOR inhibitors supports 
combination therapy approaches and a Phase I/II clinical trial of PQR309 in combination with eribulin 
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Table IX-4 : Analysis of PTB in 13 patients.  
The table indicates the exact day of the drug administration cycle the biopsy was taken, the delay after 
the last dose of oral PQR309, the 1mg dose-normalized Area Under the Curve from the beginning and 













Figure IX-1 : Activation of phosphorylation sites in the PI3K-mTOR signaling axis after 21 days of 
treatment with PQR309.  
The graphs on the left hand side show the change of the level of phosphorylation of a specific 
phosphorylation site while the patient is on therapy, in comparison to the baseline (first biopsy, 
equivalent to 100%). One data point represents 1 patient. The colour-code is explained in Tab. 4. The 
data-point corresponds to the mean of two independent measurements of the respective phospho-protein 
per biopsy and time-point. On the right hand side, patients were divided into one group, whose tumors 
grew despite therapy (round symbols), and a second group, whose tumors shrank (square symbols). 
Growth or shrinkage was defined by the best response of each patient. We considered all lesions that 







Figure IX-2 : Infiltration of the tumor with CD3, CD4, CD8 and FoxP3 positive immune cells (panels 
A-D, as indicated).  
Red dots = immune infiltrates in patients with tumor growth. Green dots = immune infiltrates in patients 
with tumor shrinkage. Left-hand column: Quantification of immune infiltrates. Right-hand column: 







Suppl. Figure IX-1  








Suppl. Figure IX-2  
Glucose levels and treatment of hyperglycemia in patients with hyperglycemia grade 3-4. Individual 








Suppl. Figure IX-3 
Changes of the expression level of 88 mRNAs associated with PI3K-mTOR signaling after 21 days of 
treatment with PQR309. PDGFRA is the only mRNA showing a trend towards upregulation. No 








Suppl. Figure IX-4 
Full panel of phospho-sites analysed in addition to those presented in Fig. 1. The colour-code is 
explained in Tab. 4. 
 
 




X. Global Discussion and Perspective 
 
These three diverse projects provide novel insights on the impact of PDPN and other treatments on the 
mTOR/PI3K/Akt pathway. We showed that podoplanin was responsible for the Akt-driven activation 
of the EGFR pathway and a mechanism of resistance for the squamous cell carcinomas upon treatments. 
Then we treated mice harboring pNET malignancy with a combination of radionuclide and Everolimus, 
where the mTOR inhibit in a critical dose-dependent manner. These results contradict previous studies 
in a non-appropriate rat model that stopped all the clinical trials for this potential combination treatment. 
Finally, we analyzed paired human biopsies confirming the efficacy of the investigational dual 
mTOR/PI3K inhibitor and the inhibition of the phospho-proteins in the metastasis as a surrogate of the 
primary tumor. The inhibition could eventually predict the response to this compound that received this 
year an orphan drug designation from the FDA for primary central nervous system lymphoma (PCNSL) 
and an EMA orphan drug designation for Diffuse Large B-cell Lymphoma. A more general perspective 
on this central pathway for cancer can be considered along several points based on the recent research, 
preclinical and clinical data : 
 
Firstly, while the inhibitors concentrated their studies on solid tumors, hematological cancers should be 
targeted as well. [I didn’t really understand how the following sentences support your first sentence here 
about hematological cancers. Is it obvious to everyone else? Otherwise maybe spell out the link more 
clearly] Given the critical functions of mTOR in most human tissues, complete catalytic inhibition 
causes severe dose-limiting toxicities, while rapalogs also suffer from the drawbacks associated with 
lack of tissue specificity and unwanted disruption of mTORC2 (Saxton & Sabatini 2017). Rapalogues 
do not fully suppress mTOR activity or translation but ATP-competitive mTOR inhibitors could 
overcome these problems (Hsieh et al. 2012; Turner et al. 2017b). The lack of predictive biomarkers is 
a major challenge and opportunity of targeted therapies. A new generation of compounds is now being 
tested and developed according to our understanding of the resistance mechanisms to TKI. 
 
Secondly, isoform-selective PI3K inhibitors have seen promising success in early- and late-stage clinical 
trials for solid and hematological malignancies, highlighting the potential for isoform-selective PI3K 
therapeutics (Thorpe et al. 2015). In order to reduce toxicities while stabilizing or increasing the effect, 
a pulsatile as opposed to continuous treatment should be tested in early phase clinical trials. 
 
We should decipher the effect of these inhibitors on the immune system and the tumor 
microenvironment. The effect of an inhibition of this pathway can either enhance or inhibit diverse 
subsets of innate and adaptive immune cells. Many xenograft-based preclinical studies do not address 
this aspect of the side effects of the drug and possibly bias the results towards combinations with 




checkpoint inhibitors or potential vaccines cancer. For these reasons, for our preclinical combination 
treatment with Everolimus, we used an engineered mouse model with a fully competent immune system. 
Isoform selective PI3K inhibitors should also prevent this type of interactions with the immune system. 
 
AGC inhibitors have demonstrated preclinical and preliminary clinical efficacy against cancer. 
Although the toxicity profile is usually manageable, as single agents, the efficacy is limited. Therefore, 
current trials tend to combine AGC inhibitors with other compounds, and many trials try to enrich the 
study population with patients with activated AGC-kinase dependent signaling, e.g., an activated PI3K-
Akt-mTOR axis (Temple 2010). The adequate way to demonstrate pathway activation in a clinical 
setting is still a matter of debate. One potential strategy is to break the growth dynamic with an AGC 
kinase inhibitor, and then use combination partners to either target mechanisms of resistance (such as 
PI3K or ROCK inhibitors) or address alternative targets (e.g., the immune-environment). To our 
knowledge, it remains to be demonstrated whether AGC inhibitors influence antigen expression or 
modifying immunogenicity, two major prerequisites for efficacy in immunotherapies.  
 
Finally, after our phase 1 study, matching patients with the relevant combination of drugs is the pinnacle 
of personalized medicine / precision medicine. Because treating patients with single RTK inhibitors 
results within some weeks or months in acquired resistance, preclinical data support the testing of 
combinations with approved TKI, especially in breast cancer (Turner et al. 2017a). However, with more 
combinations than cancer patients and knowing that only 3% of cancer patients are involved in clinical 
trials, we should re-think our approach to approving new drugs based on a phase III trial comparing vs 
the gold standard of treatment. New or forgotten approaches like basket trials and umbrella trials could 
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